
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

36606589
CN-22-992
10.2174/1570159X21666230105110834
Medicine, Neurology, Pharmacology, Neuroscience
Paradigms and Success Stories of Natural Products in Drug Discovery Against Neurodegenerative Disorders (NDDs)
Singh Sukhwinder 1
Chib Shivani 2
Akhtar Md. Jawaid 3
Kumar Bhupinder 14*
Chawla Pooja A. 1*
Bhatia Rohit 1*
1 Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy Moga, Punjab, 142001, India;
2 Department of Pharmacology, ISF College of Pharmacy Moga, Punjab, 142001, India;
3 Department of Pharmaceutical Chemistry, College of Pharmacy, National University of Science and Technology, PO620, PC 130 Azaiba, Bousher, Muscat, Oman;
4 Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar, Garhwal, Uttarakhand, 246174, India
* Address correspondence to these authors at the Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy Moga, Punjab, 142001, India; E-mails: pvchawla@gmail.com, bhatiarohit5678@gmail.com, bhupinderkumar25@gmail.com
06 11 2023
2024
22 6 9921015
16 5 2022
17 10 2022
19 10 2022
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Neurodegenerative disorders (NDDs) are multifaceted complex disorders that have put a great health and economic burden around the globe nowadays. The multi-factorial nature of NDDs has presented a great challenge in drug discovery and continuous efforts are in progress in search of suitable therapeutic candidates. Nature has a great wealth of active principles in its lap that has cured the human population since ancient times. Natural products have revealed several benefits over conventional synthetic medications and scientists have shifted their vision towards exploring the therapeutic potentials of natural products in the past few years. The structural mimicking of natural compounds to endogenous ligands has presented them as a potential therapeutic candidate to prevent the development of NDDs. In the presented review, authors have summarized demographical facts about various NDDs including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and various types of sclerosis in the brain. The significant findings of new active principles of natural origin along with their therapeutic potentials on NDDs have been included. Also, a description of clinical trials and patents on natural products has been enlisted in this compilation. Although natural products have shown promising success in drug discovery against NDDs, still their use is associated with several ethical issues which need to be solved in the upcoming time.

Keywords

Neurodegenerative disorders
natural products
Alzheimer’s disease
Parkinson’s disease
drug discovery
clinical trials
==== Body
pmc1 INTRODUCTION

Healthcare professionals attribute human health and well-being to cardinal activities of translational science including drug discovery and development. Machine learning [1], artificial intelligence [2], structure-based drug discovery [3], drug repurposing [4], and in-silico methods [5] are being deployed to get a move on drug discovery and development. The development in pharmacotherapy over years has been largely supported by natural products and their structural modifications. The broad structural diversity and multidimensional chemical structures of isolated natural products make them a distinctive fount-head for lead molecules [6].

Degenerative nerve diseases, also known as neurodegenerative disorders (NDDs) may be caused genetically or due to chemical or toxic agents, viruses, or medical conditions including stroke, tumor, and alcoholism. NDDs include, but are not limited to Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD), Friedreich ataxia (FA), and Amyotrophic lateral sclerosis (ALS); AD and PD are the most common NDDs [7]. Oxidative stress has been identified and pointed out the most as a cause of brain impairment in neurodegenerative diseases [8-10]. In consonance with the recent report by Alzheimer’s disease association, as many as 6.2 million Americans are currently living with Alzheimer's disease among which 72% are 75 and above in age. Moreover, deaths have increased by 145% between 2000 and 2019 [11, 12]. Surprisingly, an estimated 1.2 million people could be living with PD in the United States by 2030 [13]. The prevalence of HD has been raised in the US (13.7/10000 persons) [14], UK [15], Italy (3.9/100000) [16], and countries across the globe. Besides, the prevalence of Friedreich ataxia in Central Europe has been reported to be 1:20000 to 1:50000 [17], and the incidence of ALS to be between 0.6 and 3.8 per 100000 person-years, which was higher in Europe ranging from 2.1 to 3.8 per 100 000 person-years [18].

Despite a huge number of synthesized drugs for numerous diseases, the customary problems encountered with synthetic drugs include resistance and toxicity [19]. Moreover, the total expense size of the drug journey from synthesis to marketing has shifted largely the interests of researchers to drug repositioning and repurposing [20]. Even with significant advancements in the pharmaceutical field, currently employed drugs in contemporary therapy provides symptomatic treatment and focus on providing improvement in motor ad non-motor symptoms [21-24]. However, increasing the number of computational web resources, strengthening the toxicity predicting algorithms, upgrading virtual screening methods, and better lead identification and optimization are still major challenges in drug discovery [25].

Contrastingly, natural products have taken a grip on the scientific interests in the discovery of lead molecules due to the vast range of scaffolds with multifaceted physicochemical and therapeutic activities and budget research. The historical use of natural products in form of concentrated concoctions, powders, and dried parts for the treatment of ailments has provided intellectual stimulus or molecular templates for the synthesis of about fifty percent of conventionally synthesized drugs [26]. Surprisingly, studies have revealed people's bias for natural drugs over synthetic ones [27, 28]. Notwithstanding, the multidimensional nature of drug discovery requires the establishment of safety, efficacy, and pharmacokinetic data of natural drug products which bring into use the advent of modern technologies such as artificial intelligence and microfluidics. These technological and computational promotions have opened new avenues to process multiplexed natural products and utilize their scaffolds to innovate and derive useful drug molecules [29].

In the current review, the authors have reviewed and prepared a compile-up of NDDs, the importance of natural products in their treatment, and success stories including patents, clinical trials, and marketed formulations of the natural products for NDDs in the most effective way.

2 NEURODEGENERATION AND DISORDERS

Endoplasmic reticulum stress and intensifying neuronal loss are the common characteristics of neurodegeneration. NDDs, by disrupting the communication between brain-spinal cord neural cells and muscles affect many bodily activities including balance, breathing, cardiac functions, talking, walking, and other movements [30]. Although, NDDs have been classified based on cognitive disorders, clinical examinations, extrapyramidal and pyramidal movement disorders, Neuropathic evaluation at autopsy is considered to be the current diagnostic gold standard that classifies NDDs into four main types viz. amyloidosis, tauopathies, synucleinopathies, and TDP-43 Proteinopathies [31]. At least some characteristics of amyloid protein are found in almost all NDDs, amyloid-like filamentous aggregates are found within neuronal and glial cytoplasm. Moreover, extracellular deposits of amyloid can also be found as plaques in brain parenchyma or in the form of amyloid angiopathy in the walls of blood vessels. The presence of β-Amyloid (Aβ), a proteolytic product of amyloid precursor protein deposits in parenchyma as senile plaques and neuronal tau inclusions is an elucidating feature of AD [32, 33].

NDDs having a pathological accumulation of tau proteins (microtubule-associated phosphoprotein) are classified as tauopathies [34] and generally subdivided into primary and secondary tauopathies. In the bargain, synucleinopathies are characterized by the aggregation of α-synuclein (presynaptic protein), a protein constituent of Lewy bodies that are found in PD. Also, TDP-43, a nuclear protein possessing functions to modulate gene splicing, transcriptional repression, and RNA metabolism are implicated in the inclusion bodies found within the cytoplasm and nucleus in NDDs. The presence of abnormal TDP-43 can be found in PD, ALS, and Argyrophilic grain disease (AGD) [31, 35].

3 ROLE OF NATURAL PRODUCTS IN NDDs

Despite a long history of conventional use and safety credence for natural products, they have woefully received less attention than chemically synthesized drugs [36]. Neurohealth-promoting properties of natural products ranging from improving cognitive function to alleviating NDD’s symptoms including depression, memory loss, and poor cognition are being practiced by traditional medicine practitioners [37-39]. Studies have reported the use of various plant and animal species as pro-cognitive agents and treatment options for several neurological and psychological disorders [40-42]. Considering the ability to modulate the other drug molecular activities, different drugs are provided in combination as per the disease complexity [38].

In the recent decade, natural products have been intensively explored under the spotlight for the discovery and development of novel and effective drug products. The multitargeted nature of phytochemicals at the molecular level makes them perfect to be developed and employed in therapeutics [43]. Potent disease-modifying and -treating actions of phytochemicals have been scientifically established for several NDDs including PD [44], AD [38], ALS [45], and other serious NDDs. Natural products have been a fertile source for the discovery and development of novel therapeutics. Natural products from various classes have been discovered for the potential to treat NDDs, and an update on the compilation is covered further. Fig. (1) schematically describes the targets via which natural products have been noted to act in order to prevent and treat NDDs.

3.1 Alkaloids

These are generally nitrogen-containing, basic organic compounds having mostly complex cyclic structures and the property of being alkali-like. Various alkaloidal entities such as donepezil, galanthamine, caffeine, memantine, and berberine have been scientifically proven to possess the potential for the treatment of NDDs. Fig. (2) includes the chemical structures of neuroprotective alkaloids.

3.1.1 Apomorphine

Lipophilicity and affinity of apomorphine for dopaminergic receptors are attributed to the tetracycline ring present in its structure. The efficacy of apomorphine and levodopa are noted to be almost overlapping [46]. The bioavailability of apomorphine is very low due to extensive hepatic first-pass metabolism. Administration of apomorphine has been reported to relieve symptoms of PD and reduce the intermittent “off” periods. Contrastingly, antagonistic activity for serotonergic (5HT2A, 5HT2B, 5HT2C) and adrenergic (α2A, α2B, α2C) receptors has been noted [47]. Additionally, subcutaneous administration of apomorphine has prevented PD-associated motor impairment. It is noted to have better symptom controllability than other long-acting dopamine agonists [48].

3.1.2 Berberine

It is an isoquinoline alkaloid obtained from Chinese medicinal plants including berberis, Hydrastis Canadensis, and Coptis Chinensis. Berberine is noted for its significant neuroprotective role mainly for AD, PD, and HD. It significantly improves AD cases by improving neurotransmission, inhibiting senile plaque and NFTs formation, and inhibiting Tau hyperphosphorylation [49, 50]. Mechanisms behind these significant activities are the inhibitory potential of berberine for cholinesterase (AChE and BuChE), β-site amyloid precursor protein cleaving enzyme 1 (BACE1) [51, 52], Glycogen synthase kinase 3 (GSK-3), oxidants, and inflammation [50].

In PD, the onset of disease or symptoms is alleviated by mainly restoring the dopamine levels and dopaminergic neurotransmission in the brain. Monoamine oxidase enzyme B (MAO-B) is a mitochondrial enzyme that catalyzes the oxidative deamination of monoaminergic neurotransmitters such as Dopamine and 5-Hydroxytryptamine (5-HT) [53, 54]. Past studies have revealed the MAO-B inhibitory activity of berberine which leads to its neuroprotective function in PD [50]. Moreover, docking results have shown that synthetic derivatives obtained from berberine in recent years also possessed significant MAO-B inhibiting properties [55]. Additionally, the neurotoxin-preventive potential has also been justified by researchers [56].

Mutated huntingtin gene and resulting polyglutamine tract are mainly responsible for the development of HD. Induction of autophagy-lysosomal pathway (whose impairment is known to cause HD [57]) is a lead strategy for preventing the development of HD. Autophagy triggering activity of berberine could lead to retardation towards HD progression [58, 59]. Besides, the anti-neurotoxic, anti-neuroinflammatory, and anti-convulsion properties of berberine have been well identified [60].

3.1.3 Caffeine

Epidemiological investigations and animal evidence firmly support that the widely consumed psychoactive substance caffeine possesses beneficial properties for cognitive and motor improvement in PD. Caffeine, by abrogating lipopolysaccharide-induced oxidative stress and neuroinflammation [61], inhibiting adenosine A2A receptor activation, reducing tau hyperphosphorylation, and accumulation of misfolded proteins is reported to provide beneficial effects in PD and AD cases [62]. Interestingly, epidemiological and preclinical studies have shown a lower risk of AD and PD with moderate caffeine consumption (3-5 mg/kg) [63].

3.1.4 Avicine

It is a benzo phenanthridine alkaloid obtained from the roots of Zanthoxylum rigidum. Plazas et al., [64] have reported the highly potent reversible-mixed inhibitory activity of avicine and nitidine against acetylcholinesterase enzymes (AChE and BChE). Also, the compounds were found to moderately inhibit MAO-A (IC50 = 0.41 ± 0.02 µM) enzyme and Aβ1-42 (IC50 = 5.56 ± 0.94 µM) aggregation warranting the therapeutic possibilities of avicine for AD treatment.

3.1.5 Harmine

Harmine is a β-carboline alkaloid abundantly found in Peganus harmala L. Studies have attributed the pharmacological anti-Alzheimer activity of harmine to its inhibitory activity for AChE, oxidation, and inflammation. Harmine decreased the brain levels of GABA which is implicated in many neurological diseases. Also, it was reported to inhibit AChE in rat endothelial brain (REB) cells [65]. Harmaline, an analog to harmine was found to be more effective (2 mg/kg) than harmine (20 mg/kg) at a relatively lower dose [66].

The antiparkinsonian effects of harmine comparable to levodopa have been documented as well. The water-soluble form of harmine i.e. harmine hydrochloride was found to have anti-cataleptogenic (haloperidol-induced catalepsy) effect at doses of 2.5 and 5 mg/kg. Additionally, harmine at the same doses reduced oligokinesia induced by the administration of 30 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin [67]. Furthermore, harmine was found to time- and dose-dependently degrade different forms of α-synuclein. It upregulated PSMD1 subunit of the ubiquitin-proteasome system to promote α-synuclein degradation by enhancing PKA phosphorylation [68].

3.1.6 Huperzine A

It is a promising anti-Alzheimer alkaloid of sesquiterpene class extracted from firmoss Huperzia serrata having potent, selective, and reversibly inhibiting properties for the AChE enzyme. The AChE inhibiting activity of huperzine A is more potent than donepezil, galantamine, and rivastigmine [69]. Huperzine A inhibits AChE by regulating the accumulation of Aβ accumulation [70]. Microwave-assisted H. serrata green extract prevented cortical neurons exposed to glutamate from neurotoxicity and hence increased neuronal survival. Interestingly, two phenolic acids, caffeic acid, and ferulic acid were found to synergize the neuroprotective effects of huperzine A via the extracellular-signal-regulated kinase (ERK) pathway [71]. Moreover, huperzine is known to inhibit transferrin receptor protein 1 (TFR1) whose upregulation is implicated in increased iron uptake by neuronal cells and the development of AD [70].

3.1.7 Piperine

The pharmacological effects of piperine on the central nervous system including anti-convulsant, antidepressant, and anti-ischaemic are already known. Additionally, the anti-Alzheimer activity of piperine has been corroborated by recent studies. Piperine prevented altered neurotransmission, oxidative-nitrosative stress, and hippocampal neurotransmission in intracerebroventricularly infused streptozocin-induced Alzheimer’s disease in experimental mouse models [72]. The results from preclinical studies suggest that piperine easily crosses BBB and is thus effective for neurological disorders such as AD, PD, and HD [73]. Piperine has been noticed to promote autophagy flux in SNCA overexpression-induced PD cell and mouse models. PIP treatment was found to attenuate olfactory and motor deficits accompanied by degradation of pathological SNCA in the olfactory bulb, an accumulation of which is one of the earliest non-motor symptoms of PD [74]. In addition to the above, the combination of piperine with quercetin has been experimentally noted to be effective in treating iron supplement- and rotenone-induced PD in rats [75].

Additionally, Salman et al., concluded the anti-huntington activity of piperine against 3-nitropropionic acid (3NP)-induced neuropathology in animals. Piperine treatment reduced neuronal loss and astrocytes activation in the striatal brain region. Also, piperine prevented and alleviated biochemical, behavioral, immunohistochemical, and histological alterations in 3-nitropropionic acid administered male Wistar rats [76].

3.1.8 Capsaicin

Capsaicin (8-Methyl-N-vanillyl-6-nonenamide), a major alkaloid found in capsicums has been repeatedly noted to be effective against several neurological-related proteinopathies including chemical-induced AD and PD [77]. In recent studies, capsaicin has been noted to alleviate AD-related pathologies including neuro-inflammation and degradation, and tau hyperphosphorylation. Aβ burden was found to be reduced in APP/PS1 mice by switching amyloid precursor protein towards α cleavage [78]. Additionally, capsaicin treatment has declined the amount of tau and Aβ in the hippocampal homogenate of STZ-induced AD rat models [79].

In addition to the above, researchers have concluded that capsaicin exerts an apoptosis-alleviation effect in the 6-OHDA-induced PD cell model by regulation of apoptosis-causing genes viz. Actg1 and Gsta2 [80]. In a study, researchers determined the radical and superoxide anion reducing the potential of capsaicin in PD model flies. Capsaicin was found to alleviate lipid peroxidation (LPO) (by 1.8 fold), glutathione-S-transferase (GST) (by 1.26 fold), and MAO activity (by 1.6 fold) while significantly increasing dopamine (1.56 fold) and glutathione (by 1.37 fold) content [81].

3.2 Flavonoids

Flavonoids are polyphenolic secondary plant metabolites, commonly found in fruits and vegetables in the form of aglycones or glycosides. Possessing a common skeleton of phenyl-benzopyran (C6-C3-C6), they are classified into several categories including flavones, flavonols, flavanones, isoflavones, flavonoids, and anthocyanidins. These are among the most intensively explored phyto-secondary metabolites owing to indispensable health benefits [82-84]. Various flavonoids such as naringenin, nobiletin [85], cocoa [86], fisetin, and apigenin have been noted to show significant antioxidant and neuroprotective functions. Fig. (3) presents the chemical structures of neuroprotective flavonoids.

3.2.1 Naringenin

The compound has already been reported to be neuroprotective due to its antioxidative and anti-inflammatory properties [87, 88]. In a study, the effect of naringenin nanoemulsion against Aβ-induced neurotoxicity in human neuroblastoma cell lines (SH-SY5Y) was determined. Naringenin alleviated direct neurotoxicity caused by Aβ by reducing amyloidogenesis indicated by the downregulation of BACE and APP expression. Furthermore, the levels of tau phosphorylated proteins were reduced [89]. Additionally, naringenin has been noted to favorably and strongly bind to collapsing response mediator protein-2 (CRMP 2), a neurotherapeutics target, and disrupts kinase-mediated phosphorylation [90]. Recently, various naringenin derivatives possessing anti-AD properties have been designed and synthesized [91, 92].

Paraquat is an oxidative stress-causing herbicide and is implicated in the development of PD. Studies have reported that naringenin inhibits or modulates paraquat-induced RNA expression of SNCA, DAT, β-catenin, caspase-3, and BDNF genes, and hence exhibits neuroprotection against paraquat-induced neurodegeneration [93]. Naringenin has improved behavioral response and neurotoxicity caused by several PD-causing chemical agents including MPTP [94], 6-OHDA [95], and LPS [96]. Moreover, the binding and inhibitory potential of naringenin (-12.0 kcal/mol) for the active site of MAO-B has also been reported [97].

In addition to the above, the neuroprotective effects of naringenin against 3-NP-induced Huntington-like symptoms have also been reported. Naringenin administration caused a reduction in the glial fibrillary acidic protein (GFAP) and attenuation of neuronal cell death in Wistar albino rats [98].

3.2.2 Apigenin

The neuroprotective actions of apigenin have been well explored by scientists across the globe. Apigenin has been found to possess neuroprotective properties in AD-associated inflammation by reducing microglial activation, modulation of expression of inflammatory cytokines, and increasing the expression of brain-derived neurotrophic factor (BDNF) in-vitro [99]. The expression of glycogen synthase kinase -3 (GSK-3), a critical molecule modulating major hallmarks of AD, is reported to be decreased on apigenin (50 mg/kg) administration resulting in suppressed BACE1 expression and reduced tau hyperphosphorylation [100]. Besides, apigenin has been noted to provide neuroprotection against acrylonitrile by inhibiting TLR4/NF-κB signaling pathway and neuron apoptosis [101].

The anti-PD potential of apigenin has also been investigated in recent years. In a study, the apigenin was found to prevent neuroinflammation in substantia niagra pars compacta, attenuated NF-κB gene expression, and inhibited the rotenone-induced release of proinflammatory cytokines IL-6 and TNF-α. Additionally, apigenin prevented the reduction in mRNA expression of GDNF and BDNF in rats [102].

In ethidium bromide-induced multiple sclerosis experimental rat models, apigenin prevented neurochemical and neurobehavioural defects by modulating the levels of c-JNK/p38MAPK and myelin basic protein in brain and CSF homogenate. Moreover, the imbalanced levels of apoptotic markers (Bax, Bcl-2, caspase-3) and inflammatory cytokines (TNF-α, IL-1β) were reduced by apigenin treatment [39]. Also, the oxidative stress amelioration potential of apigenin in SH-SY5Y [103] and dendritic cells of experimental autoimmune encephalomyelitis (EAE) mice [104] has been documented.

3.2.3 Luteolin

Luteolin (5,7,3',4'-Tetrahydroxyflavone) is a flavone type of flavonoid mainly found in Reseda luteola. The anti-AD potential of luteolin has been largely supported by its ER stress suppression [105] and anti-neuroinflammatory actions for IL-1β, IL-6, TNF-α, COX-2, NO, and iNOS. In a triple transgenic mouse model of AD, luteolin (1 to 10 µM) improved spatial learning and ameliorated memory defects along with inhibited LPS-induced cell proliferation, ER stress marker GRP78 increase, and excessive cytokine release in astrocytes [106]. In another study on transgenic fly lines having wild-type human Aβ42, luteolin dose-dependently reduced AChE, catalase (CAT), GST, LPO, PCC, and caspase-3 and caspase-9 activity. Additionally, luteolin reduced the expression of Aβ42 expression dose-dependently [107].

In several PD models, luteolin has been reported to act by inhibiting the release of and/or decreasing the levels and activity of lactate dehydrogenase, caspase-3, IL-1β, TNF-α, and reducing mRNA levels of Lrrk2 [108, 109]. Interestingly, the adjuvant therapy value of palmitoylethanolamide/luteolin to treat dyskinesia and camptocormia has been reported [110].

Besides, luteolin is reported to interact with the mutant form of HTT. Administration of luteolin to transgenic drosophila HD model flies resulted in a dose-dependent decrease in oxidative stress and delay in loss of climbing activity. This suggested the effectiveness of luteolin to reduce symptoms of HD [111].

3.2.4 Quercetin

Quercetin (pentahydroxyflavone), having a bitter flavor is commonly found in capers, red onions, and kale. In addition to its antioxidant and anti-inflammatory activities, other activities including hypolipidemic, hypoglycemic, activities have been intensively explored and documented [112, 113]. The molecular mechanisms behind the neuroprotective effects of quercetin in AD chiefly include the potentiality to down- or up-regulation of cytokines via protein kinase c (PKc), c-Jun N-terminal kinase (JNK), nuclear factor (Nrf2), paraoxonase-2, and mitogen-activated protein kinase (MAPK) signaling cascades and alteration is antioxidant enzymes (catalase, GST) [114-116]. Additionally, the derivative, quercetin-O-glucuronide has been noted to alleviate Aβ1-42cognitive toxicity by modulating the gut-brain axis in AD mice models [117]. In a recent study, quercetin (25 and 50 mg/kg) has been noted to up-regulate the gene expression of ADAM-10 and ADAM-17 GENES to prevent neurotransmission impairment and cognitive deficits in AlCl3-induced AD rats [118].

In rotenone-induced PD animal models, quercetin (50 mg/kg p.o) supplementation improved neurotransmitter levels by increasing the levels of antioxidant enzymes and hence improved cognitive and motor functions and reduced behavioral depression [119]. Additionally, quercetin-rich extract rich from Chrysobalanus icaco has shown potent NADP oxidase inhibition (IC50 = 8.1 μg/mL) with a docking score of ΔG = -8.3 kcal/mol on NADPH oxidase [120]. Also, quercetin has shown neuroprotective effects in 6-OHDA-lesioned rat PD models by reducing mitochondrial damage and α-synuclein accumulation and mitigating neuronal death in vivo [121]. Interestingly, the nanoparticle formulation of quercetin has shown the potential to inhibit mHTT aggregation in the HD cell model [122].

3.2.5 Fisetin

Fisetin (3,3′,4′,7-Tetrahydroxyflavone), a potent antioxidant flavone compound is mainly found in strawberries, apples, onions, and parrot trees. Fisetin has shown inhibitory potential toward the aggregation of tau fragment K18. Fisetin directly interacts and strongly binds with tau K18 protein, prevents the β-strand formation at critical hexapeptide motifs, and prevents tau aggregation [123].

In rotenone-induced rat PD models, fisetin (10 to 20 mg/kg p.o.) reversed rotenone-induced mitochondrial enzyme changes, striatal dopamine levels, and normalized antioxidant enzyme levels [124]. In another study, fisetin significantly suppressed 6-OHDA-mediated activation and elevation of caspase-3, caspase-9, and expression of oxidative stress-related genes in human neuronal SH-SY5Y cells by activating PI3K-Akt signaling [125]. Besides, fisetin has been noted to prevent degeneration in PD by inhibiting protein aggregation, mitochondrial dysfunction, glutathione loss, and inflammatory conditions [126]. Furthermore, fisetin has been noted to inhibit α-syn fibrillation by binding with- and providing structural rigidity to α-syn and hence delaying the onset of structural transitions [127].

In multiple hSOD-1 mutated Drosophila models of ALS, fisetin has lessened both mutant and wild hSOD-1 in vivo and in vitro and has shown significant neuroprotection by attenuating motor impairments, regulating redox homeostasis, and reducing ROS damage [128].

3.2.6 Hesperidin

Hesperidin is a flavanone glycoside majorly present in fruits (sweet oranges), vegetables (lemon), and polyherbal formulations. Its potential to suppress oxidation and inflammation contributes to cardioprotective, antihyperlipidemic, antidiabetic, and antihypertensive properties. For neuroprotection in AD, hesperidin has been noted to act by attenuating inflammation, caspase activation, raised p-Tau levels, and Aβ-42 and AchE overactivity in AlCl3-intoxicated rats [129, 130], and scopolamine-induced AD-like rat model [131].

In PD, hesperidin has shown significant neuroprotective effects by intracellular calcium homeostasis, restoring dopamine levels, improved motor function, ameliorating oxidative stress and mitochondrial dysfunction, downregulating gsk3β, lrrk2, polg, and casp9 genes in 6-OHDA-toxicated SH-SY5Y cellular [132], and zebrafish model of PD [133], and iron-induced Drosophila model of PD [134].

3.2.7 Curcumin

Curcumin is an indispensable compound commonly obtained from the rhizomes of Curcuma longa. The intensive exploration of the molecule across the globe has revealed its significant valuable properties to be employed in the therapeutics of cancer, NDDs, infectious diseases, and metabolic syndrome. The neuroprotective effects of curcumin against AD, PD, MS, and cerebral ischaemia have been experimentally validated that evinces the pleiotropic effects of curcumin including antiapoptotic, anti-inflammatory, antioxidative, and vasculo-protective effects [135]. Mechanisms underlying its anti-AD effects include but are not limited to preventing antioxidant enzyme activity, increasing the synthesis of BDNF, reducing the levels of ROS, TNF-α, IL-1β, IL-6, malondialdehyde (MDA) [136, 137], and affecting the aggregation of tau and amyloid proteins [138, 139]. Recently, the neuroprotective effects of curcumin have been noted for several AD models such as AlCl3-induced- [140], scopolamine-induced- [137], and streptozotocin-induced rat AD model [141]. In experimental in-vitro and in-vivo AD models, curcumin has been shown to reverse neurotoxic and behavioral damages which warrants its administration as a promising approach [142].

Interestingly, the inducing effect of curcumin on IL-10, a potent anti-inflammatory, and immunosuppressive cytokine is an important mechanism behind its anti-PD effects [143]. Curcumin modulates the immune system via the cholinergic anti-inflammatory pathway by selectively stimulating α7 nicotinic acetylcholine receptors (α7-nAChR), which is a novel proposed approach to treat PD [144]. Additionally, the neuroprotective effects of curcumin for paraquat-induced PD model fibroblasts [145], rotenone-induced PD model [146], 6-OHDA-lesioned rat PD model, and PC12 cells [147] prevent mitochondrial dysfunction, alleviating oxidative stress, inhibiting AKT/mTOR signaling pathway, and reducing lipoperoxidation [148]. Furthermore, the binding of curcumin to non-amyloid β-component of α-synuclein has been hypothesized to prevent the spread of- and clarifies α-synuclein from the body [149].

In the R6/2 mice model of HD, a curcumin-supplemented diet protected from neuropathology and GI dysfunction maintained normal motor function, and conserved intestinal contractility [150]. Besides, curcumin effectively mitigated HD symptoms including metabolic derangements and ROS levels in the Drosophilia model of HD [151]. Surprisingly, curcumin supplementation has shown retardation in disease progression towards ALS and improved aerobic metabolism in a trial that prophesies its possible positive effects on ALS [152].

3.2.8 Rutin

It is citrus flavonoid glycoside between quercetin and rutoside, commonly found in vegetables, herbs, and fruits such as asparagus, tobacco, viola, buckwheat, and forsythia. In addition to hypolipidemic, anti-hypertensive, anti-allergic, anti-bacterial, antiprotozoal, and antitumor properties, the neuroprotective effects of rutin are well known [153]. Recently reported mechanisms underlying the anti-AD effect of rutin include regulation of tau hyperphosphorylation, inhibition of tau aggregation and tau oligomer-induced toxicity, and suppression of neuroinflammation by downregulating NF-κB pathway, and promotion of microglial uptake of extracellular tau oligomers [154]. Recently, Ouyang et al. developed a nanoflower formulation comprising rutin and microRNA-124. Rutin was predicted to synergize microRNA-124, which could suppress the expression of APP and BACE1 in the hippocampus of AAP/PS1 mice [155].

The anti-HD effects of rutin are too well investigated. In Caenorhabditis elegans model of HD, rutin, by controlling the expression of antioxidant enzymes, activation of protein degradation and insulin/IGF1 signaling pathways, maintained the ASH neuronal function, reduced the degeneration of their sensory terminations, and reduced polyglutamine protein aggregation [156, 157]. Also, rutin alone (25 and 50 mg/kg), and rutin along with selenium has shown significant anti-HD effects in a 3-NP-induced rat and mice model of HD evinced by restoration of biochemical, behavioral, and histological alterations which were further caused due to inhibiting astrocyte activation, increasing BDNF, and improving cholinergic and monoaminergic transmission [158, 159].

3.2.9 Mucuna

Mucuna pruriens, belonging to the Fabaceae family consists of phenolic components which execute a significant neuroprotective effect in humans. It consists of dopamine precursor L-DOPA, which is the reason for its employment in treating PD cases in Ayurvedic medicine. Additionally, the plant is used in the treatment of depressive neurosis and snakebites. Studies have shown the preventive effects of M. pruriens against neurological damage caused by bilateral carotid artery occlusion-induced global cerebral ischaemia in rats that warrants its adjuvant use to improve the life quality of PD patients [160, 161].

3.3 Terpenoids and Carotenoids

Terpenoids or isoprenoids are the largest class of plant secondary metabolites. A wide array of pharmacological properties including anticancer, antiprotozoal, antioxidant and anti-inflammatory, and neuroprotective properties have been confirmed by in-vitro, preclinical, and clinical studies. Based on the number of forming isoprene units, terpenoids are classified into monoterpenoids (C10), sesquiterpenoids (C15), and diterpenoids (C20), sesterterpenoids (C25), triterpenoids (C30), tetraterpenoids (C40) [162]. The neuroprotective effects of different terpenoids are covered below. The chemical structures of investigated terpenoids and carotenoids possessing neuroprotective activities are given in Fig. (4).

3.3.1 Crocin

Crocin (crocetin di-gentibiose ester) is a water-soluble carotenoid found in crocus and gardenia flowers. A broad range of pharmacological effects on the cardiovascular system, liver disease, joint disease, neurodegeneration, diabetes, depression, and tumor have been investigated [163]. In various AD models, crocin has caused significant alleviation of disease progression and improvement by different mechanisms including blocking Aβ-initiated apoptosis [164], preventing mitochondrial damage [165], attenuating expression of TNF-α and IL-1β mRNA [166], reducing Aβ deposition in the brain hippocampus, and reducing ROS generation via its anti-inflammatory effects [166, 167].

Additionally, crocin in doses of 10, 20, and 40mg has shown protective effects towards malathion-induced PD-like behavior in rats through anti-inflammatory effects and reducing lipoperoxidation as evinced by increased levels of GSH and decreased MDA, TNF-α, and IL-6 levels in the striatum [168].

Interestingly, the spectrum of neuroprotective effects of crocin is further extended toward HD. In Drosphilia melanogaster HD flies, crocin has been reported to prevent Escherichia coli colonization, which is implicated in HTT aggregation and HD-associated immobility [169].

3.3.2 Astaxanthin

Astaxanthin is a strong antioxidant, marine-derived ketocarotenoid, generally known as beneficial for skin problems including aging, dehydration, and wrinkles [170]. Astaxanthin could impede the development of AD by inhibiting aggregation of Aβ1-42 and hence its toxicity in PC12 cells. Although astaxanthin possesses the highest bioavailability of other carotenoids (lutein and carotene), the bioavailability can be further enhanced by carrier oils such as polysorbate 80 [171]. In Aβ1-42 in toxicated Wistar rat models of AD, astaxanthin dose-dependently and significantly reversed the cognitive and memory impairment that was evinced by reduced levels of Aβ1-42, AChE, TNF-α, oxidative stress, GSK-3β, and IRS-S307 activity in the hippocampus [172]. Sakayanathan et al. have noted that astaxanthin-s-allyl cysteine inhibited human brain AChE (IC50 = 0.80 µM) and human serum BChE (IC50 = 0.800 µM) by interacting with amino acids present in peripheral anionic and cationic site of both enzymes [173]. Being widely employed following haemorrhagic stroke, Astralgus membranaceus, by its antioxidant and anti-inflammatory action, has been noted to enhance functional recovery of the patient if treatment is started within 24 hours [174, 175].

Surprisingly, the neuroprotective effects of astaxanthin on PD have been well extended. In 1-methyl-4-phenylpyridinium (MPP+) caused PD in SH-SY5Y cells, astaxanthin, by targeting miR-7/SNCA axis, inhibited endoplasmic reticulum stress and hence abolished the promotion of apoptosis and inhibition of cell viability [176]. Similar actions were reported in rotenone-intoxicated Drosophilia melanogaster models of PD. Trans-astaxanthin (0.5 and 1.0 mg/10 g diet) inhibited the rotenone-mediated decrease of thiol content, inhibition of catalase, acetylcholinesterase, and glutathione-s-transferase activity. Additionally, the docking score of trans-astaxanthin against pro-inflammatory targets was higher than standard inhibitors [177]. In addition to the above, astragaloside IV and tetramethylpyrazine, extensively used medicines for the treatment of myocardial ischaemic conditions, the combination has shown a synergistic protective effect against cerebral ischaemic-reperfusion injury by downregulating MDA, iNOS, caspase-3, and upregulating SOD, and Bcl-2 [178].

3.3.3 Lutein

Lutein, a structural isomer of zeaxanthin is a non-provitamin A dietary carotenoid noted to have strong anti-oxidant properties in experimental studies. Having a property to preferentially accumulate in macula lutea to protect the retina from UVR-caused oxidative damage, lutein also possesses anti-inflammatory, anticarcinogenic, and skin-friendly properties [179]. In Aβ25-35-intoxicated rat PC12 cells, lutein extract from Bombyx mori yellow cocoons significantly ameliorated toxicity by attenuating ROS production, MAPKs pathway activation, apoptosis, and loss of cell viability [180]. In another study, lutein (0.1-1 µM) prevented SH-SY5Y cells from OxPL 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) toxicity indicated by decreased ROS production and prevention of loss of GSH [181].

Fernandes et al. have investigated the anti-PD effects of lutein-loaded nanoparticles in Drosphilia melanogaster models of PD. Lutein executed anti-PD effects by restoring the levels of dopamine, tyrosine hydroxylase, oxidative stress indicators, and AchE activity and hence preventing PD flies from rotenone-induced locomotor damage [182].

Although a very small search has been performed to investigate the anti-HD effects of lutein. Lutein 50 or 100 mg/kg orally (p.o.) has shown considerable anti-HD effects in 3-NP intoxicated rat models of HD by normalizing body weight, improving mitochondrial enzyme complexes, and attenuating oxidative stress [183].

3.3.4 Crocetin

It is an amphiphilic apocarotenoid dicarboxylic acid and the chief active component of saffron responsible for a broad range of pharmacological properties. It is known to be a potential autophagy inducer in AD. In N9 microglial and primary neuron cells, crocetin induced autophagy by activating STK11/LKB1 (serine/threonine kinase 11)-mediated AMP-activated protein kinase (AMPK) pathway and hence resulted in clearance of Aβ. Additionally, APMK-activation has resulted in Aβ lowering in transgenic male 5XFAD mice models of AD [184]. In another study, crocetin has significantly reduced pro-inflammatory cytokines, suppressed NF-κB activation and p53 expression in mice hippocampus, decreased levels of Aβ, and enhanced anti-inflammatory cytokines [185].

In MPTP-induced PD model animals, crocetin has exerted excellent antioxidant and anti-inflammatory effects both in vivo and in vitro. It prevented animals from MPP+ induced mitochondrial damage by regulating mitochondrial permeability transition pore (MPTP) viability and decreasing the expression of inflammatory and proinflammatory cytokines [186].

3.3.5 Beta Carotene

Beta carotene is a red-orange-colored pigment and precursor of vitamin A. Having three isomers of beta carotene i.e. alpha, beta, and gamma, the beta isomer is the most active. The natural compound is known generally for its strong antioxidant properties [187]. To investigate its effectiveness for neuroprotective effects against AD, Hira et al. injected beta carotene in 50 streptozotocin (STZ)-intoxicated male albino mice models of PD. Beta carotene (2.05 mg/kg), by exerting strong antioxidant effects, inhibiting AchE, and reducing Aβ-protein fragments attenuated STZ-induced memory deficit. Furthermore, in silico studies revealed the considerable binding capacity of beta carotene with the AchE enzyme [188].

It has been noted that PD patients have low serum levels of beta-carotene and lycopene, which may predispose them to oxidative stress and hence the development of PD [189]. Further research to investigate mechanistic pathways of beta carotene to treat or prevent PD is needed.

3.3.6 Lycopene

Lycopene is a naturally occurring and red-color contributing carotenoid pigment mainly found in tomatoes, papaya, and watermelons. Other than neuroprotection, the strong antioxidant action of lycopene contributes to the antiapoptotic, antimetastatic, and antiproliferative actions of lycopene [190]. Huang and coworkers reported that lycopene possesses the potential to prevent the development of oxidative stress-mediated AD. In cerebrocortical neurons of mouse models of AD, lycopene enhanced cell viability, increased GSH/GSSG levels, decreased production of ROS, and restored mitochondrial membrane potential. Additionally, lycopene increased synaptophysin levels, activated PI3K/Akt pathway, and reduced the ratio of cleaved caspase 3: caspase 3 which signifies its efficacious anti-AD potential [191].

Lycopene has been concluded by authors to have PD-modifying properties. It possibly acts by reducing the loss of dopaminergic neurons, showing an anti-amyloidogenic effect, and reducing ischaemic-related apoptosis [192].

3.3.7 Fucoxanthin

Fucoxanthin is a potent antioxidant allenic carotenoid that is isolated mainly from marine sources such as macroalgae and microalgae. It structurally resembles dinoxanthin and neoxanthin. After being administered orally, fucoxanthin is metabolized into fucoxanthinol and amarouciaxanthin A, which are accumulated in the heart and adipose tissues, respectively. Fucoxanthin is found to be a potential candidate against obesity, diabetes, cancer, and heart and liver diseases [193, 194].

Being a potent antioxidant and anti-inflammatory compound fucoxanthin is used in various neurological disorders such as PD, AD, and TBI. It is also known to inhibit the production of proinflammatory cytokines (TNF-a, IL-1b, and IL-6), cyclooxygenase-2 (COX-2), and nitric oxide (NO). Fucoxanthin has been noted to have hydrophobic interactions with Aβ peptides. Fucoxanthin, by interacting with Aβ prevents the conformational transition and Aβ oligomer formation. It also increases the expression of BDNF and significantly inhibits oxidative stress [195]. Additionally, fucoxanthin has been noted to inhibit LPS/ATP-induced secretion of pro-inflammatory cytokines. Fucoxanthin reduced the protein expression of ASC, NLRP3, and cleaved caspase-1 to inhibit NLRP3 inflammasome and NF-κB activation [196].

Targeting oxidative stress to be the major culprit for neuronal damage in PD, Wu et al. investigated the effect of fucoxanthin in 6-OHDA stressed PC12 cells. Results suggested that fucoxanthin acts to prevent apoptosis by targeting Keap 1 (Kelch-like ECH-associated protein 1), which is a suppressor of Nrf2 to prevent the interaction between Keap 1 and Nrf2. Besides, fucoxanthin suppressed 6-OHDA induced disruption of mitochondrial membrane potential, and intracellular ROS accumulation [197].

4 SUCCESS STORIES

The complex nature and multifactorial development of NDDs, ADRs of chemically synthesized drugs, and the development of resistance among patients have propelled scientific interest towards natural and therefrom derived molecules for novel drug development [198]. Numerous molecules have been synthesized by modifying naturally occurring molecules have been found to exhibit significant neuroprotective properties. Fig. (5) composes examples of hybrid molecules synthesized and possessing neuroprotective properties.

The exploration of natural resources including plants, minerals, and marine sources has been on trend for the past decades. The naturally occurring molecules belonging to different pharmacognostic classes have been reconnoitered intensively as evinced by accumulated literature and scientific reports. This has emerged with numerous novel and effective natural product formulations to treat NDDs. Additionally, efforts have been made to address the pharmacokinetic issues. In an attempt to enhance the biopharmaceutical and bioavailability characteristics of natural products, formulations including nanoparticles, nanocarriers, inclusion complexes, and self nano-emulsifying drug delivery systems (SNEDDS) have been developed. Table 1 [199-217] depicts the recently developed natural product formulations for the prevention and treatment of NDDs.

Additional to the above, successful research studies have continued the natural products and their formulation up to clinical trials and patents too which evinces the success of natural products in drug discovery and development. Regardless of whether it is a carcinogenic, neurological, or metabolic disorder, natural products have grabbed abundant attention for the discovery and development of novel drug molecules [243]. We have used the official website of clinical trials i.e. CLINICALTRIALS.GOV for the exploration and compilation of clinical trial studies. Table 2 [218-242] presents the clinical trial studies done on natural products to investigate neuroprotective activities. Inclusion criteria for clinical trial studies included; only completed and active studies, and those done for natural products related to neurological disorders since 2010 were selected [243]. Besides, numerous patents for natural products intended for the prevention, disease modification, or treatment of NDDs have been granted. Some examples of patents granted since 2010 are given in Table 3 [244-253]. For patents, the online database PUBCHEM and LENS.ORG (website) was used.

5 CHALLENGES AND ETHICAL ISSUES

Although a vast background of historical use and an abundance of phytochemicals, the operation from discovery to development of natural products up to mercenary has been back-breaking. The featured characteristics of natural products over conventional molecules present both advantages as well as challenges for drug discovery as well as development. Screening of natural products for target-based assays has been so onerous due to the vast libraries of extracts obtained from them. The task of pinpointing novel and serviceable natural product molecules from libraries additionally with precluding existing molecules to avoid the rediscovery of existing molecules is a laborious task [254]. Besides, the procedures of extraction span including several difficulties such as extensive duration of extraction, high energy consumption, small extract recovery, and use of petroleum-derived solvents, which are globally getting depleted gradually [255].

Additionally, collecting abundant starting material to isolate and characterize natural product molecules with biological activity is also challenging. Lack of access to enough samples has also led to difficulty in drug discovery of marine-derived natural products [256]. Besides, the intellectual property (IP) protection of naturally occurring molecules can be arduous work due to the inability to IP-protecting natural products in their existing natural form [257]. In addition, the regulations framed in United Nations 1992 Convention on Biological Diversity and Nagoya Protocol defines the need of sharing benefits with the countries where the biological material originates. This poses an auxiliary layer of complexity over the development and protection of natural products [244, 258]. Furthermore, the water insolubility, photosensitivity, poor bioavailability, BBB crossing, and physical and chemical instabilities make natural products intended for NDDs more challenging to be developed [259].

However, it has been noted and reported by authors that an ethical issue regarding the use of natural products exists regarding the safety and efficacy of the product. This highlights the need to advance the interpretation of the molecular mechanism of action of natural products [260].

CONCLUSION

As an epilogue, nature presents an abundant and outstanding source of neuroprotective natural products. The ethnobotanical use of natural products for healing several ailments including neurological disorders warrants their use in modern times too. Various classes of Phyto-secondary metabolites including alkaloids, glycosides, terpenoids, flavonoids, and combinations thereof possess significant disease-preventive and -modifying properties that are being investigated to act by crucial mechanisms. A common characteristic mode of preventing or treating NDDs is noted to be the antioxidant potential of natural products. The potent NADPH oxidase inhibitory action of quercetin and myricetin has been attributed to their significant antioxidant action against neurodegeneration as well as other diseases. Besides, the inhibiting effect on the aggregation of NDDs-causing proteins has also prevailed in their mechanism of action.

Although, several issues related to extraction, bioavailability, safety, and efficacy need to be addressed. Recent technological and scientific advances to overcome challenges in natural product drug discovery and development present special emphasis on analytical techniques, genome engineering, and cultivation systems. The number of chemical modification and formulation studies to increase the functional activity, and overall safety and efficacy characteristics have risen in recent years. Besides, the clinical trial data is an essential component needed to warrant and underline the safety of the human use of natural products. On the whole, natural products are indispensable and needed sources for drug discovery and drug development. Also, work to investigate their mechanisms of action, and improve extraction yield, efficacy, and safety is needed.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

AChE Acetylcholinesterase

AD Alzheimer’s Disease

AGD Argyrophilic Grain Disease

ALS Amyotrophic Lateral Sclerosis

ASH Amphid Single Neurons

BACE β-site Amyloid Precursor Protein Cleaving Enzyme

BDNF Brain Derived Neurotrophic Factor

BuChE Butyrylcholinesterase

DAT Dopamine Transporter

ERK Extracellular-Signal-Regulated Kinase

FA Friedreich Ataxia

GDNF Glial Cell Line Derived Neurotrophic Factor

GSH Glutathione

GSK Glycogen Synthase Kinase

HD Huntington’s Disease

hSOD Human Superoxidase Dismutase

LPO Lipid Peroxidation

MAO Monoamine Oxidase

MDA Malondialdehyde

mHTT Mutant Huntingtin

MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

NDDs Neurodegenerative Disorders

3-NP 3-Nitropropionic Acid

6-OHDA 6-Hydroxydopamine

PD Parkinson’s Disease

REB Rat Endothelial Brain

SNCA Synuclein Alpha

TFR Transferrin Receptor Protein

UVR Ultraviolet Radiation

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) Potential targets for natural products to treat NDDs.

Fig. (2) Some significant neuroprotective alkaloids.

Fig. (3) Some significant neuroprotective flavonoids.

Fig. (4) Neuroprotectant carotenoids and terpenoids.

Fig. (5) Hybrid molecules with neuroprotectant activities.

Table 1 Various formulations of natural products against neurodegenerative disorders.

S. No.	Type of Formulation	Active Natural Components	Formulation	Enhanced Features	Health Advantages	References	
1	Nanoparticles	Curcumin	Curcumin encapsulated Pluronic F127 nanoparticles and P68 + DQA curcumin	• Brain accumulation of curcumin following IV dose
• Maintenance of Aβ binding property of curcumin
• Increased cellular antioxidant activity	Treatment of AD and PD	[199]
[200]	
Silibinin	Silibinin-human serum albumin (HSA) nanoparticles	• Increased neuroprotective and antioxidative activity than free silibinin	Treatment of AD	[201]	
Catechin	Trehalose-conjugated, catechin-loaded polylactide nanoparticles	• Enhanced cell proliferation against polyQ aggregates	Treatment of HD	[202]	
Quercetin	Quercetin-loaded nanoparticles	• Antiamyloidogenic effect at lower concentration of quercetin
• Improved overall performance than free quercetin	Treatment of HD	[203]	
Epigallocatechin-3-gallate	Epigallocatechin-3-gallate/Ascorbic acid nanoparticles	• More effective to reduce motor defects and depression-like behaviour	Treatment of HD and other neurological disorders	[204]	
2	Inclusion complexes	Morin	Morin/hydroxypropyl-β-cyclodextrin inclusion complex	• Improved solubility
• Improved solubility and dissolution rate	Anti-inflammatory and antihyperalgesic	[205]	
Quercetin	Quercetin-methyl-β-cyclodextrin inclusion complex	• Improved solubility and purity	Potential anti-AD effects.	[206]	
Crocetin	Crorcetin-γ-cyclodextrin inclusion complex	• Enhanced bioavailability across blood-brain barrier	Treatment of AD	[207]	
Curcumin	Curcumin/hydroxypropyl-β-cyclodextrin inclusion complex	• Antioxidant and anti-inflammatory effect
• Increased AUC values	Treatment of AD	[208]	
3	Self-nano/ micro emulsifying drug delivery system (SNEDDS/ SMEDDS)	Fisetin	Fisetin-SNEDDS	• Improved oral bioavailability of fisetin
• Low dose required for activity	Treatment of PD Anti-PD effects	[209]
[210]	
Oxyresveratrol	Oxyresveratrol SMEDDS	• 4-Times reduction of dose	Treatment of AD	[211]	
4	Nanospheres	Curcumin	Curcumin and selenium nanoparticles loaded nanospheres	• Enhanced therapeutic efficacy	Treatment of AD	[212]	
Amantadine	Amantadine-loaded methacrylate nanosphere	• Improved bioavailability	Treatment of ALS	[213]	
5	Micelles	Linoleic acid	Lactoferrin-conjugated linoleic acid micelles	• Enhanced in vivo distribution in brain
• Good hemocompatibility	Treatment of AD	[214]	
Curcumin	Curcumin loaded polymeric micelles	• Excellent intraocular biocompatibility	Diagnosis and management of AD	[215]	
Morin	Morin hydrate-loaded micellar nanocarriers	• High blood and brain drug concentration	Treatment of AD	[216]	
Hydroxytyrosol	Hydroxytyrosol-loaded Pluronic + dequalinium micellar nanocarriers	• Improved protection to cytotoxicity and oxidative stress	Anti-PD effects	[217]	

Table 2 Details of various clinical trials completed/ongoing for natural products against neurodegenerative diseases.

S. No.	Clinical Trial Number	Official Title	Intervention/ Treatment Drug	Location(s)	Actual Enrollment	Phase Number	Status	Actual/ Anticipated Completion Date	References	
1	NCT00470418	Development of NIC5-15 in the treatment of Alzheimer's disease	NIC5-15	New York	15	2	Completed	March 2010	[218]	
2	NCT04663854	Evaluation of therapeutic effects of trehalose in patients with Alzheimer's disease	Trehalose	Iran, Islamic republic of	20	1	Recruiting	August 2022	[219]	
3	NCT01928420	A single site, randomized, double-blind, placebo-controlled trial of NIC5-15 in subjects with Alzheimer's disease	NIC5-15	New York	30	2	Completed	June 2014	[220]	
4	NCT01190735	Caffeine for motor manifestations of Parkinson's Disease: An open-label, dose-response study	Caffeine alkaloid	Canada	28	2	Completed	February 2011	[221]	
5	NCT02061878	A randomized controlled study to evaluate the effect of bexarotene- an RXR agonist – on beta-amyloid and apolipoprotein E metabolism in healthy subjects	Bexarotene	Florida	12	1	Completed	November 2014	[222]	
6	NCT00963846	Huperzine for cognitive and functional impairment in Schizophrenia	Huperzine	Connecticut	56	2	Completed	December 2012	[223]	
7	NCT01333865	A study of memantine hydrochloride (Namenda) for cognitive and behavioural impairment in adults with autism spectral disorders	Memantine	Massachusetts	25	4	Completed	July 2014	[224]	
8	NCT04843813	Lutein and multiple sclerosis experimental studies (LuMES)	Dietary supplement: Lutein	Illinois	60	Not applicable	Recruiting	March 2023	[225]	
9	NCT03476044	Effect of selenium of succinylcholine-induced postoperative myalgia after adult sinuscopic procedures	Selenium	Egypt	80	3	Completed	March 2020	[226]	
10	NCT01022229	Phase 3 study of a compound natural health product in children with ADHD	Dietary supplement: Compound natural health product	Canada	16	3	Completed	November 2015	[227]	
11	NCT04484454	ProdromeNeuro: An Open-Label Study of Omega 3 Oil Nutritional Supplementation for Aging-related cognitive decline	Dietary Supplement: ProdromeNeuro Omega 3 Oil Nutritional Supplement	California	20	Not applicable	Completed	March 2021	[228]	
12	NCT05066503	Natural therapy for delirium in elderly hospitalized subjects	Dietary Supplement: 260279 active study product	Arkansas	45	Not applicable	Recruiting	March 2023	[229]	
13	NCT03575676	Phase iia, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3355 in J-Huntington disease patients with chorea movements	SOM3355	Spain	32	2	Completed	August 2019	[230]	
14	NCT03761849	A randomized, multicenter, double-blind, placebo-controlled, phase iii clinical study to evaluate the efficacy and safety of intrathecally administered RO7234292 (rg6042) in patients with manifest Huntington's Disease	RO7234292	Albama	791	3	Recruiting	March 2022	[231]	
15	NCT04000594	An open-label adaptive multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of RO7234292 in csf and plasma, and safety and tolerability following intrathecal administration in patients with Huntington's Disease	RO7234292	Netherlands, London, and Manchester	12	1	Completed	January 2022	[232]	
16	NCT02336633	Metabolic Intervention Using Resveratrol in Patients with Huntington's disease	Dietary supplement: Resveratrol	Paris	102	Not applicable	Completed	January 2020	[233]	
17	NCT00980694	Bioavailability of ubiquinol in Huntington's disease	Dietary supplement: ubiquinol	New York	6	1	Completed	July 2012	[234]	
18	NCT01458470	A trial of memantine as a symptomatic treatment for early Huntington Disease; a phase iib study	Memantine	Canada	19	2	Completed	November 2012	[235]	
19	NCT04478734	Multicentric trial on the use of combined therapy of thiamine and biotine in patients with Huntington Disease	Moderate doses of thiamine y biotin	Spain	24	2	Not yet recruiting	June 2023	[236]	
20	NCT01245530	Probable Alzheimer type dementia compare INM-176 1200~1600mg/day with donepezil 5~10mg/day of safety and efficacy to randomization, multicenter, double-blind, double-dummy, parallel phase iii clinical study	INM-176, Aricept	Korea, Republic of	280	3	Completed	March 2011	[237]	
21	NCT02914769	Antidepressant effects of ayahuasca: a randomized placebo-controlled trial in treatment-resistant depression	Ayahuasca	Brazil	35	2	Completed	December 2016	[238]	
22	NCT04785300	ALSENLITE: an open-label pilot study of senolytics for Alzheimer's Disease	Quercetin, and dasatinib	Minnesota	20	2	Enrolling by invitation	June 2024	[239]	
23	NCT04685590	Phase ii clinical trial to evaluate the safety and feasibility of senolytic therapy in Alzheimer's Disease	Quercetin and dasatinib	North Carolina	48	2	Recruiting	January 2032	[240]	
24	NCT02104752	Curcumin as a novel treatment to improve cognitive dysfunction in schizophrenia	Curcumin	California	39	2	Completed	October 2017	[241]	
25	NCT01811381	Curcumin and yoga exercise effects in veterans at risk for Alzheimer's Disease	Curcumin	California	80	2	Not recruiting	December 2020	[242]	

Table 3 List of patents granted for natural products against neurodegenerative diseases.

S. No.	Patent Title	Patent Claims	Year of Grant	Patent Number	References	
1	Method of treating neurological conditions with oleandrin	Oleandrin contains composition to treat neurological conditions including stroke, HD, PD, AD, ALS, autism and diabetic neuropathy	January 2018	US 9877979 B2	[244]	
2	Nutritional supplement for the prevention of cardiovascular disease, Alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance	A supplement in form of a drink or food comprising ten synergistic components (such as lycopene, naringenin, quercetin, hesperidin, diindolylmethane, glycine) capable of lowering the risk of AD	September 2011	US 8017147 B2	[245]	
3	Pharmaceutical compositions containing phosphatidylserine and curcumin	A stable pharmaceutical composition or food supplement containing curcumin and phosphatidylserine has potential to treat brain aging-related disorders including AD	July 2016	US 9381204 B2	[246]	
4	Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism	Administering flavonoids to patients can treat schizophrenia and autism by inhibiting the activation of STAT3	July 2014	US 8778894 B2	[247]	
5	Buccal and sublingual cannabinoid formulations and method of making the same	A troche formulation containing PEG, cannabis extract compound has the potential to treat AD, PD, HD, ADHD, depression, cancer, Crohn's disease, and ulcerative colitis	April 2021	EP 3160451 B1	[248]	
6	Phenolic compositions derived from apple skin and uses thereof	Pharmaceutical composition having extract fraction of apple skin composing flavonol components (such as quercetin, quercetin-3-O-galactoside etc). The composition has the potential to treat autoimmune, neurodegenerative (AD, PD, and sclerosis), metabolic, and vascular disorders	December 2016	US 9511107 B2	[249]	
7	Herbal composition for reducing ADD/ADHD and method thereof	An herbal formulation comprising herbal extracts to treat symptoms associated with ADHD	March 2013	US 8394429 B2	[250]	
8	Nutraceutical composition that comprises an extract of Andean shilajit, for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral aging	Nutraceutical formulation comprising a blend of shilajit, folic acid, vitamin B6, and B12. The composition has the potential to treat neurodegenerative diseases including AD, PD, and senile dementia	July 2014	US 8784804 B2	[251]	
9	Cannabinoid-containing plant extracts as neuroprotective agents	Plant extract to be used for prevention of treatment of neurogenerative diseases including ALS, HD, PD, AD, and prion disease	March 2014	US 8673368 B2	[252]	
10	Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic Aa amyloidosis, and other amyloid disorders	Green tea extract composing catechins for the treatment of amyloid diseases	January 2012	CA 2440293 C	[253]
==== Refs
REFERENCES

1 Patel L. Shukla T. Huang X. Ussery D.W. Wang S. Machine learning methods in drug discovery. Molecules 2020 25 22 5277 10.3390/molecules25225277 33198233
2 Chan H.C.S. Shan H. Dahoun T. Vogel H. Yuan S. Advancing drug discovery via artificial intelligence. Trends Pharmacol. Sci. 2019 40 8 592 604 10.1016/j.tips.2019.06.004 31320117
3 Batool M. Ahmad B. Choi S. A structure-based drug discovery paradigm. Int. J. Mol. Sci. 2019 20 11 2783 10.3390/ijms20112783 31174387
4 Parvathaneni V. Kulkarni N.S. Muth A. Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov. Today 2019 24 10 2076 2085 10.1016/j.drudis.2019.06.014 31238113
5 Shaker B. Ahmad S. Lee J. Jung C. Na D. In silico methods and tools for drug discovery. Comput. Biol. Med. 2021 137 104851 10.1016/j.compbiomed.2021.104851 34520990
6 Rijo P. Mori M. Natural products as an important source in drug discovery. Curr. Pharm. Des. 2020 26 24 2805 2806 10.2174/138161282624200625104355 32586237
7 Medline Plus. Degenerative nerve diseases. Health Topics 2021 2022
8 Butterfield D.A. Perspectives on oxidative stress in Alzheimer’s disease and predictions of future research emphases. J. Alzheimers Dis. 2018 64 s1 S469 S479 10.3233/JAD-179912 29504538
9 Jiang T. Sun Q. Chen S. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. Prog. Neurobiol. 2016 147 1 19 10.1016/j.pneurobio.2016.07.005 27769868
10 Santos J.R. Gois A.M. Mendonça D.M. Freire M.A. Nutritional status, oxidative stress and dementia: the role of selenium in Alzheimer’s disease. Front. Aging Neurosci. 2014 6 206 10.3389/fnagi.2014.00206 25221506
11 Facts and figures. Alzheimer's and Dementia, 2021 2022 17(3) 327 406
12 Kumar R. Kumar V. Kumar B. Thakur A. Dwivedi A.R. Multi-target-directed ligands as an effective strategy for the treatment of Alzheimer’s disease. Curr. Med. Chem. 2022 29 10 1757 1803 10.2174/0929867328666210512005508 33982650
13 Foundation, P.s. Understanding Parkinson's. Parkinson's foundation 2022 2022
14 Yohrling G. Raimundo K. Crowell V. Lovecky D. Vetter L. Seeberger L. Prevalence of huntington’s disease in the US (954). AAN Enterprises 2020
15 Furby H. Siadimas A. Rutten-Jacobs L. Rodrigues F.B. Wild E.J. Natural history and burden of Huntington’s disease in the UK: A population‐based cohort study. Eur. J. Neurol. 2022 29 8 2249 2257 10.1111/ene.15385 35514071
16 Riccò M. Vezzosi L. Balzarini F. Gualerzi G. Ranzieri S. Prevalence of huntington disease in Italy: A systematic review and meta-analysis. Acta Biomed. 2020 91 Suppl. 3 119 127 32275276
17 Wedding I.M. Kroken M. Henriksen S.P. Selmer K.K. Fiskerstrand T. Knappskog P.M. Berge T. Tallaksen C.M.E. Friedreich ataxia in Norway - an epidemiological, molecular and clinical study. Orphanet J. Rare Dis. 2015 10 1 108 10.1186/s13023-015-0328-4 26338206
18 Longinetti E. Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr. Opin. Neurol. 2019 32 5 771 776 10.1097/WCO.0000000000000730 31361627
19 Ribeiro A. Abreu R.M.V. Dias M.M. Barreiro M.F. Ferreira I.C.F.R. Antiangiogenic compounds: well-established drugs versus emerging natural molecules. Cancer Lett. 2018 415 86 105 10.1016/j.canlet.2017.12.006 29222042
20 Ballard C. Aarsland D. Cummings J. O’Brien J. Mills R. Molinuevo J.L. Fladby T. Williams G. Doherty P. Corbett A. Sultana J. Drug repositioning and repurposing for Alzheimer disease. Nat. Rev. Neurol. 2020 16 12 661 673 10.1038/s41582-020-0397-4 32939050
21 Breijyeh Z. Karaman R. Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules 2020 25 24 5789 10.3390/molecules25245789 33302541
22 Armstrong M.J. Okun M.S. Diagnosis and treatment of Parkinson disease. JAMA 2020 323 6 548 560 10.1001/jama.2019.22360 32044947
23 Hardiman O. Al-Chalabi A. Chio A. Corr E.M. Logroscino G. Robberecht W. Shaw P.J. Simmons Z. van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 2017 3 1 17071 10.1038/nrdp.2017.71 28980624
24 Singh K. Kumar P. Bhatia R. Mehta V. Kumar B. Akhtar M.J. Nipecotic acid as potential lead molecule for the development of GABA uptake inhibitors; structural insights and design strategies. Eur. J. Med. Chem. 2022 234 114269 10.1016/j.ejmech.2022.114269 35306287
25 Sharma H. Chawla P.A. Bhatia R. 1, 3, 5-Pyrazoline derivatives in cns disorders: synthesis, biological evaluation and structural insights through molecular docking. CNS & Neurological Disorders- Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2020 19 6 448 465
26 Chopra B. Dhingra A.K. Natural products: A lead for drug discovery and development. Phytother. Res. 2021 35 9 4660 4702 10.1002/ptr.7099 33847440
27 Meier B.P. Lappas C.M. The influence of safety, efficacy, and medical condition severity on natural versus synthetic drug preference. Med. Decis. Making 2016 36 8 1011 1019 10.1177/0272989X15621877 26683247
28 Meier B.P. Dillard A.J. Osorio E. Lappas C.M. A behavioral confirmation and reduction of the natural versus synthetic drug bias. Med. Decis. Making 2019 39 4 360 370 10.1177/0272989X19838527 30896330
29 Thomford N. Senthebane D. Rowe A. Munro D. Seele P. Maroyi A. Dzobo K. Natural products for drug discovery in the 21st century: Innovations for novel drug discovery. Int. J. Mol. Sci. 2018 19 6 1578 10.3390/ijms19061578 29799486
30 Motor Neuron Disease. Disorders 2019 2022
31 Dugger B.N. Dickson D.W. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 2017 9 7 a028035 10.1101/cshperspect.a028035 28062563
32 Tiwari S. Atluri V. Kaushik A. Yndart A. Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int. J. Nanomedicine 2019 14 5541 5554 10.2147/IJN.S200490 31410002
33 Bhatia R. Chakrabarti S.S. Kaur U. Parashar G. Banerjee A. Rawal R.K. Multi-Target Directed Ligands (MTDLs): Promising coumarin hybrids for Alzheimer’s disease. Curr. Alzheimer Res. 2021 18 10 802 830 10.2174/1567205018666211208140551 34879800
34 Shi Y. Zhang W. Yang Y. Murzin A.G. Falcon B. Kotecha A. van Beers M. Tarutani A. Kametani F. Garringer H.J. Vidal R. Hallinan G.I. Lashley T. Saito Y. Murayama S. Yoshida M. Tanaka H. Kakita A. Ikeuchi T. Robinson A.C. Mann D.M.A. Kovacs G.G. Revesz T. Ghetti B. Hasegawa M. Goedert M. Scheres S.H.W. Structure-based classification of tauopathies. Nature 2021 598 7880 359 363 10.1038/s41586-021-03911-7 34588692
35 Ratti A. Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016 138 Suppl. 1 95 111 10.1111/jnc.13625 27015757
36 Barkat M.A. Goyal A. Barkat H.A. Salauddin M. Pottoo F.H. Anwer E.T. Herbal medicine: Clinical perspective and regulatory status. Comb. Chem. High Throughput Screen. 2021 24 10 1573 1582 10.2174/1386207323999201110192942 33176638
37 Farzaei M.H. Shahpiri Z. Mehri M.R. Bahramsoltani R. Rezaei M. Raeesdana A. Rahimi R. Medicinal plants in neurodegenerative diseases: perspective of traditional persian medicine. Curr. Drug Metab. 2018 19 5 429 442 10.2174/1389200219666180305150256 29512453
38 Gregory J. Vengalasetti Y.V. Bredesen D.E. Rao R.V. neuroprotective herbs for the management of Alzheimer’s disease. Biomolecules 2021 11 4 543 10.3390/biom11040543 33917843
39 Singh K. Bhatia R. Kumar B. Singh G. Monga V. Design strategies, chemistry and therapeutic insights of multi-target directed ligands as antidepressant agents. Curr. Neuropharmacol. 2022 20 7 1329 1358 34727859
40 Dey A. Gorai P. Mukherjee A. Dhan R. Modak B.K. Ethnobiological treatments of neurological conditions in the Chota Nagpur Plateau, India. J. Ethnopharmacol. 2017 198 33 44 10.1016/j.jep.2016.12.040 28017696
41 Amoateng P. Quansah E. Karikari T.K. Asase A. Osei-Safo D. Kukuia K.K.E. Amponsah I.K. Nyarko A.K. Medicinal plants used in the treatment of mental and neurological disorders in Ghana. Evid. Based Complement. Alternat. Med. 2018 2018 1 14 10.1155/2018/8590381 30671131
42 Kumar R.R. Singh L. Thakur A. Singh S. Kumar B. Role of vitamins in neurodegenerative diseases: A review. CNS Neurol. Disord. Drug Targets 2022 21 9 667 773 10.2174/1871527320666211119122150 34802410
43 Khan H. Ullah H. Martorell M. Valdes S.E. Belwal T. Tejada S. Sureda A. Kamal M.A. Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects. Semin. Cancer Biol. 2021 69 200 211 10.1016/j.semcancer.2019.07.023 31374244
44 Naoi M. Maruyama W. Shamoto-Nagai M. Disease-modifying treatment of Parkinson’s disease by phytochemicals: targeting multiple pathogenic factors. J. Neural Transm. (Vienna) 2021 34654977
45 Mohi-ud-din R. Mir R.H. Shah A.J. Sabreen S. Wani T.U. Masoodi M.H. Akkol E.K. Bhat Z.A. Khan H. Plant-derived natural compounds for the treatment of amyotrophic lateral sclerosis: An update. Curr. Neuropharmacol. 2022 20 1 179 193 10.2174/1570159X19666210428120514 33913406
46 Carbone F. Djamshidian A. Seppi K. Poewe W. Apomorphine for Parkinson’s disease: Efficacy and safety of current and new formulations. CNS Drugs 2019 33 9 905 918 10.1007/s40263-019-00661-z 31473980
47 Jenner P. Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat. Disord. 2016 33 Suppl. 1 S13 S21 10.1016/j.parkreldis.2016.12.003 27979722
48 Müller T. An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease. Expert Opin. Pharmacother. 2020 21 14 1659 1665 10.1080/14656566.2020.1787379 32640853
49 Chen Y. Chen Y. Liang Y. Chen H. Ji X. Huang M. Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance. Biomed. Pharmacother. 2020 121 109670 10.1016/j.biopha.2019.109670 31810131
50 Fan D. Liu L. Wu Z. Cao M. Combating neurodegenerative diseases with the plant alkaloid berberine: Molecular mechanisms and therapeutic potential. Curr. Neuropharmacol. 2019 17 6 563 579 10.2174/1570159X16666180419141613 29676231
51 Huang M. Jiang X. Liang Y. Liu Q. Chen S. Guo Y. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β-amyloid in APP/tau/PS1 mouse model of Alzheimer’s disease. Exp. Gerontol. 2017 91 25 33 10.1016/j.exger.2017.02.004 28223223
52 Wu Y. Chen Q. Wen B. Wu N. He B. Chen J. Berberine reduces Aβ42 deposition and tau hyperphosphorylation via ameliorating endoplasmic reticulum stress. Front. Pharmacol. 2021 12 640758 10.3389/fphar.2021.640758 34349640
53 Kumar B. Sheetal S. Mantha A.K. Kumar V. Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders. RSC Advances 2016 6 48 42660 42683 10.1039/C6RA00302H
54 Kumar B. Gupta V. Kumar V. A perspective on monoamine oxidase enzyme as drug target: challenges and opportunities. Curr. Drug Targets 2016 18 1 87 97 10.2174/1389450117666151209123402 26648064
55 Ribaudo G. Zanforlin E. Canton M. Bova S. Zagotto G. Preliminary studies of berberine and its semi-synthetic derivatives as a promising class of multi-target anti-parkinson agents. Nat. Prod. Res. 2018 32 12 1395 1401 10.1080/14786419.2017.1350669 28691859
56 Kim; Cho, K.H.; Shin, M.S.; Lee, J.M.; Cho, H.S.; Kim, C.J.; Shin, D.H.; Yang, H.J. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson’s disease. Int. J. Mol. Med. 2014 33 4 870 878 10.3892/ijmm.2014.1656 24535622
57 Croce K.R. Yamamoto A. A role for autophagy in Huntington’s disease. Neurobiol. Dis. 2019 122 16 22 10.1016/j.nbd.2018.08.010 30149183
58 Sahu K. Singh S. Devi B. Singh C. Singh A. A review on the neuroprotective effect of berberine against chemotherapy- induced cognitive impairment. Curr. Drug Targets 2022 23 9 913 923 10.2174/1389450123666220303094752 35240956
59 Jiang W. Wei W. Gaertig M.A. Li S. Li X.J. Therapeutic effect of berberine on Huntington’s disease transgenic mouse model. PLoS One 2015 10 7 e0134142 10.1371/journal.pone.0134142 26225560
60 Dey A. Mukherjee A. Plant-Derived Alkaloids: A promising window for neuroprotective drug discovery. Discovery and Development of Neuroprotective Agents from Natural Products. Brahmachari G. Elsevier 2018 237 320 10.1016/B978-0-12-809593-5.00006-9
61 Badshah H. Ikram M. Ali W. Ahmad S. Hahm J.R. Kim M.O. Caffeine may abrogate LPS-induced oxidative stress and neuroinflammation by regulating Nrf2/TLR4 in adult mouse brains. Biomolecules 2019 9 11 719 10.3390/biom9110719 31717470
62 Ikram M. Park T.J. Ali T. Kim M.O. Antioxidant and neuroprotective effects of caffeine against Alzheimer’s and Parkinson’s disease: Insight into the role of Nrf-2 and A2AR signaling. Antioxidants 2020 9 9 902 10.3390/antiox9090902 32971922
63 Kolahdouzan M. Hamadeh M.J. The neuroprotective effects of caffeine in neurodegenerative diseases. CNS Neurosci. Ther. 2017 23 4 272 290 10.1111/cns.12684 28317317
64 Plazas E. Hagenow S. Avila Murillo M. Stark H. Cuca L.E. Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Aβ1-42 aggregation. Bioorg. Chem. 2020 98 103722 10.1016/j.bioorg.2020.103722 32155491
65 Jiang B. Meng L. Zou N. Wang H. Li S. Huang L. Cheng X. Wang Z. Chen W. Wang C. Mechanism-based pharmacokinetics-pharmacodynamics studies of harmine and harmaline on neurotransmitters regulatory effects in healthy rats: Challenge on monoamine oxidase and acetylcholinesterase inhibition. Phytomedicine 2019 62 152967 10.1016/j.phymed.2019.152967 31154274
66 Li S.P. Wang Y.W. Qi S.L. Zhang Y.P. Deng G. Ding W.Z. Ma C. Lin Q.Y. Guan H.D. Liu W. Cheng X.M. Wang C.H. Analogous β-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice. Front. Pharmacol. 2018 9 346 10.3389/fphar.2018.00346 29755345
67 Nurmaganbetov Z.S. Arystan L.I. Muldaeva G.M. Haydargalieva L.S. Adekenov S.M. Experimental study of antiparkinsonian action of the harmine hydrochloride original compound. Pharmacol. Rep. 2019 71 6 1050 1058 10.1016/j.pharep.2019.06.002 31605892
68 Cai C.Z. Zhou H.F. Yuan N.N. Wu M.Y. Lee S.M.Y. Ren J.Y. Su H.X. Lu J.J. Chen X.P. Li M. Tan J.Q. Lu J.H. Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. Phytomedicine 2019 61 152842 10.1016/j.phymed.2019.152842 31048127
69 Tsai S.J. Huperzine-A, a versatile herb, for the treatment of Alzheimer’s disease. J. Chin. Med. Assoc. 2019 82 10 750 751 10.1097/JCMA.0000000000000151 31305343
70 Friedli M.J. Inestrosa N.C. Huperzine a and its neuroprotective molecular signaling in Alzheimer’s disease. Molecules 2021 26 21 6531 10.3390/molecules26216531 34770940
71 Callizot N. Campanari M.L. Rouvière L. Jacquemot G. Henriques A. Garayev E. Poindron P. Huperzia serrata extract ‘NSP01’ with neuroprotective effects-potential synergies of huperzine a and polyphenols. Front. Pharmacol. 2021 12 681532 681532 10.3389/fphar.2021.681532 34526893
72 Wang C. Cai Z. Wang W. Wei M. Kou D. Li T. Yang Z. Guo H. Le W. Li S. Piperine attenuates cognitive impairment in an experimental mouse model of sporadic Alzheimer’s disease. J. Nutr. Biochem. 2019 70 147 155 10.1016/j.jnutbio.2019.05.009 31207354
73 Tripathi A.K. Ray A.K. Mishra S.K. Molecular and pharmacological aspects of piperine as a potential molecule for disease prevention and management: evidence from clinical trials. Beni. Suef Univ. J. Basic Appl. Sci. 2022 11 1 16 10.1186/s43088-022-00196-1 35127957
74 Li R. Lu Y. Zhang Q. Liu W. Yang R. Jiao J. Liu J. Gao G. Yang H. Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model. Autophagy 2022 18 3 559 575 34092198
75 Sharma S. Raj K. Singh S. Neuroprotective effect of quercetin in combination with piperine against rotenone- and iron supplement–induced Parkinson’s disease in experimental rats. Neurotox. Res. 2020 37 1 198 209 10.1007/s12640-019-00120-z 31654381
76 Salman M. Tabassum H. Parvez S. Piperine mitigates behavioral impairments and provides neuroprotection against 3-nitropropinoic acid-induced Huntington disease-like symptoms. Nutr. Neurosci. 2022 25 1 100 109 10.1080/1028415X.2020.1721645 32093571
77 Tyagi S. Shekhar N. Thakur A.K. Protective role of capsaicin in neurological disorders: An overview. Neurochem. Res. 2022 47 6 1513 1531 10.1007/s11064-022-03549-5 35150419
78 Wang J. Sun B.L. Xiang Y. Tian D.Y. Zhu C. Li W.W. Liu Y.H. Bu X.L. Shen L.L. Jin W.S. Wang Z. Zeng G.H. Xu W. Chen L.Y. Chen X.W. Hu Z. Zhu Z.M. Song W. Zhou H.D. Yu J.T. Wang Y.J. Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice. Transl. Psychiatry 2020 10 1 230 10.1038/s41398-020-00918-y 32661266
79 Shalaby M.A. Nounou H.A. Deif M.M. The potential value of capsaicin in modulating cognitive functions in a rat model of streptozotocin-induced Alzheimer’s disease. Egypt. J. Neurol. Psychiat. Neurosurg. 2019 55 1 48 10.1186/s41983-019-0094-7
80 Liu J. Liu H. Zhao Z. Wang J. Guo D. Liu Y. Regulation of Actg1 and Gsta2 is possible mechanism by which capsaicin alleviates apoptosis in cell model of 6-OHDA-induced Parkinson’s disease. Biosci. Rep. 2020 40 6 BSR20191796 10.1042/BSR20191796 32537633
81 Siddique Y.H. Naz F. Jyoti S. Effect of capsaicin on the oxidative stress and dopamine content in the transgenic Drosophila model of Parkinson’s disease. Acta Biol. Hung. 2018 69 2 115 124 10.1556/018.69.2018.2.1 29888671
82 Hernández-Rodríguez P. Baquero L.P. Larrota H.R. Flavonoids: Potential therapeutic agents by their antioxidant capacity. Bioactive Compounds. Campos M.R.S. Woodhead Publishing 2019 265 288 10.1016/B978-0-12-814774-0.00014-1
83 Dias M.C. Pinto D.C.G.A. Silva A.M.S. Plant flavonoids: Chemical characteristics and biological activity. Molecules 2021 26 17 5377 10.3390/molecules26175377 34500810
84 Ullah A. Munir S. Badshah S.L. Khan N. Ghani L. Poulson B.G. Emwas A.H. Jaremko M. Important flavonoids and their role as a therapeutic agent. Molecules 2020 25 22 5243 10.3390/molecules25225243 33187049
85 Nakajima A. Ohizumi Y. Potential benefits of nobiletin, a citrus flavonoid, against Alzheimer’s disease and Parkinson’s disease. Int. J. Mol. Sci. 2019 20 14 3380 10.3390/ijms20143380 31295812
86 Ludovici V. Barthelmes J. Nägele M.P. Enseleit F. Ferri C. Flammer A.J. Ruschitzka F. Sudano I. Cocoa, blood pressure, and vascular function. Front. Nutr. 2017 4 36 10.3389/fnut.2017.00036 28824916
87 Zaidun N.H. Thent Z.C. Latiff A.A. Combating oxidative stress disorders with citrus flavonoid. Naringenin. Life Sci. 2018 208 111 122 10.1016/j.lfs.2018.07.017 30021118
88 Singh S. Sharma A. Monga V. Bhatia R. Compendium of naringenin: Potential sources, analytical aspects, chemistry, nutraceutical potentials and pharmacological profile. Crit. Rev. Food Sci. Nutr. 2023 63 27 8868 8899 10.1080/10408398.2022.2056726 35357240
89 Md S. Gan S.Y. Haw Y.H. Ho C.L. Wong S. Choudhury H. In vitro neuroprotective effects of naringenin nanoemulsion against β-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation. Int. J. Biol. Macromol. 2018 118 Pt A 1211 1219 10.1016/j.ijbiomac.2018.06.190 30001606
90 Lawal M. Olotu F.A. Soliman M.E.S. Across the blood-brain barrier: Neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer’s disease using bioinformatics and computational tools. Comput. Biol. Med. 2018 98 168 177 10.1016/j.compbiomed.2018.05.012 29860210
91 Wu J. Kou X. Ju H. Zhang H. Yang A. Shen R. Design, synthesis and biological evaluation of naringenin carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. Lett. 2021 49 128316 10.1016/j.bmcl.2021.128316 34391893
92 Mi J. He Y. Yang J. Zhou Y. Zhu G. Wu A. Liu W. Sang Z. Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. Lett. 2022 60 128574 10.1016/j.bmcl.2022.128574 35065231
93 Ahmad M.H. Fatima M. Ali M. Rizvi M.A. Mondal A.C. Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson’s disease. Neuropharmacology 2021 201 108831 10.1016/j.neuropharm.2021.108831 34655599
94 Sugumar M. Sevanan M. Sekar S. Neuroprotective effect of naringenin against MPTP-induced oxidative stress. Int. J. Neurosci. 2019 129 6 534 539 10.1080/00207454.2018.1545772 30433834
95 Gaba B. Khan T. Haider M.F. Alam T. Baboota S. Parvez S. Ali J. Vitamin E. Vitamin E. Loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson’s disease model. BioMed Res. Int. 2019 2019 1 20 10.1155/2019/2382563 31111044
96 Chen C. Wei Y.Z. He X.M. Li D.D. Wang G.Q. Li J.J. Zhang F. Naringenin produces neuroprotection against LPS-induced dopamine neurotoxicity via the inhibition of microglial NLRP3 inflammasome activation. Front. Immunol. 2019 10 936 10.3389/fimmu.2019.00936 31118933
97 Govindasamy H. Magudeeswaran S. Kandasamy S. Poomani K. Binding mechanism of naringenin with monoamine oxidase – B enzyme: QM/MM and molecular dynamics perspective. Heliyon 2021 7 4 e06684 10.1016/j.heliyon.2021.e06684 33898820
98 Salman M. Sharma P. Alam M.I. Tabassum H. Parvez S. Naringenin mitigates behavioral alterations and provides neuroprotection against 3-nitropropinoic acid-induced Huntington’s disease like symptoms in rats. Nutr. Neurosci. 2022 25 9 1898 1908 33856270
99 Dourado N.S. Souza C.S. de Almeida M.M.A. Bispo da Silva A. dos Santos B.L. Silva V.D.A. De Assis A.M. da Silva J.S. Souza D.O. Costa M.F.D. Butt A.M. Costa S.L. Neuroimmunomodulatory and Neuroprotective Effects of the Flavonoid Apigenin in in vitro Models of Neuroinflammation Associated With Alzheimer’s Disease. Front. Aging Neurosci. 2020 12 119 10.3389/fnagi.2020.00119 32499693
100 Alsadat A.M. Nikbakht F. Hossein Nia H. Golab F. Khadem Y. Barati M. Vazifekhah S. GSK-3β; as a target for apigenin-induced neuroprotection against Aβ 25–35 in a rat model of Alzheimer’s disease. Neuropeptides 2021 90 102200 10.1016/j.npep.2021.102200 34597878
101 Zhao F. Dang Y. Zhang R. Jing G. Liang W. Xie L. Li Z. Apigenin attenuates acrylonitrile-induced neuro-inflammation in rats: Involved of inactivation of the TLR4/NF-κB signaling pathway. Int. Immunopharmacol. 2019 75 105697 10.1016/j.intimp.2019.105697 31352326
102 Anusha C. Sumathi T. Joseph L.D. Protective role of apigenin on rotenone induced rat model of Parkinson’s disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis. Chem. Biol. Interact. 2017 269 67 79 10.1016/j.cbi.2017.03.016 28389404
103 Kim Y.J. Cho E.J. Lee A.Y. Seo W.T. Apigenin ameliorates oxidative stress-induced neuronal apoptosis in SH-SY5Y Cells. Han’guk Misaengmul, Saengmyong Konghakhoe Chi. 2021 49 2 138 147 10.48022/mbl.2009.09006
104 Ginwala R. Bhavsar R. Moore P. Bernui M. Singh N. Bearoff F. Nagarkatti M. Khan Z.K. Jain P. Apigenin modulates dendritic cell activities and curbs inflammation via RelB inhibition in the context of neuroinflammatory diseases. J. Neuroimmune Pharmacol. 2021 16 2 403 424 10.1007/s11481-020-09933-8 32607691
105 Tana; Nakagawa, T. Luteolin ameliorates depression-like behaviors by suppressing ER stress in a mouse model of Alzheimer’s disease. Biochem. Biophys. Res. Commun. 2022 588 168 174 10.1016/j.bbrc.2021.12.074 34959189
106 Kou J.J. Shi J.Z. He Y.Y. Hao J.J. Zhang H.Y. Luo D.M. Song J.K. Yan Y. Xie X.M. Du G.H. Pang X.B. Luteolin alleviates cognitive impairment in Alzheimer’s disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation. Acta Pharmacol. Sin. 2022 43 4 840 849 34267346
107 Ali F. Rahul; Jyoti, S.; Naz, F.; Ashafaq, M.; Shahid, M.; Siddique, Y.H. Therapeutic potential of luteolin in transgenic Drosophila model of Alzheimer’s disease. Neurosci. Lett. 2019 692 90 99 10.1016/j.neulet.2018.10.053 30420334
108 Elmazoglu Z. Yar Saglam A.S. Sonmez C. Karasu C. Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson’s disease and inflammatory pathways. Drug Chem. Toxicol. 2020 43 1 96 103 10.1080/01480545.2018.1504961 30207190
109 Qin L. Chen Z. Yang L. Shi H. Wu H. Zhang B. Zhang W. Xu Q. Huang F. Wu X. Luteolin-7-O-glucoside protects dopaminergic neurons by activating estrogen-receptor-mediated signaling pathway in MPTP-induced mice. Toxicology 2019 426 152256 10.1016/j.tox.2019.152256 31381935
110 Brotini S. Palmitoylethanolamide/luteolin as adjuvant therapy to improve an unusual case of camptocormia in a patient with Parkinson’s disease: A case report. Innov. Clin. Neurosci. 2021 18 10-12 12 14 35096476
111 Hasan S.Y. Rahul; Varshney, H.; Mantasha, I.; Shahid, M. Effect of luteolin on the transgenic Drosophila model of Huntington’s disease. Comput. Toxicol. 2021 17 100148 10.1016/j.comtox.2020.100148
112 Hashemzaei M. Far A.D. Yari A. Heravi R.E. Tabrizian K. Taghdisi S.M. Sadegh S.E. Tsarouhas K. Kouretas D. Tzanakakis G. Nikitovic D. Anisimov N.Y. Spandidos D.A. Tsatsakis A.M. Rezaee R. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. Oncol. Rep. 2017 38 2 819 828 10.3892/or.2017.5766 28677813
113 Zu G. Sun K. Li L. Zu X. Han T. Huang H. Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus. Sci. Rep. 2021 11 1 22959 10.1038/s41598-021-02248-5 34824300
114 Zhang X.W. Chen J.Y. Ouyang D. Lu J.H. Quercetin in animal models of Alzheimer’s disease: A systematic review of preclinical studies. Int. J. Mol. Sci. 2020 21 2 493 10.3390/ijms21020493 31941000
115 Zaplatic E. Bule M. Shah S.Z.A. Uddin M.S. Niaz K. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease. Life Sci. 2019 224 109 119 10.1016/j.lfs.2019.03.055 30914316
116 Lema Abdullahi A. Lema A. Jibrin K. Nuraddeen W. Alexander E. Ameliorative role of nutraceutical quercetin and its derivatives against cognitive impairment process induced by lead exposure in Drosophila melanogaster (Fruit Fly). Iraqi J. Pharm Sci. 2021 30 2 135 142
117 Xu M. Huang H. Mo X. Zhu Y. Chen X. Li X. Peng X. Xu Z. Chen L. Rong S. Yang W. Liu S. Liu L. Quercetin‐3‐ O ‐Glucuronide Alleviates Cognitive Deficit and Toxicity in Aβ 1‐42 ‐Induced AD‐Like Mice and SH‐SY5Y Cells. Mol. Nutr. Food Res. 2021 65 6 2000660 10.1002/mnfr.202000660 33141510
118 Elfiky A.M. Mahmoud A.A. Elreedy H.A. Ibrahim K.S. Ghazy M.A. Quercetin stimulates the non-amyloidogenic pathway via activation of ADAM10 and ADAM17 gene expression in aluminum chloride-induced Alzheimer’s disease rat model. Life Sci. 2021 285 119964 10.1016/j.lfs.2021.119964 34537230
119 Madiha S. Batool Z. Tabassum S. Liaquat L. Sadir S. Shahzad S. Naqvi F. Saleem S. Yousuf S. Nawaz A. Ahmad S. Sajid I. Afzal A. Haider S. Quercetin exhibits potent antioxidant activity, restores motor and non-motor deficits induced by rotenone toxicity. PLoS One 2021 16 11 e0258928 10.1371/journal.pone.0258928 34767546
120 Pantoja L.V.P.S. Trindade S.S.A. Carneiro A.S. Silva J.P.B. Paixão T.P. Romeiro C.F.R. Moraes C.S.P. Pinto A.C.G. Raposo N.R.B. Andrade M.A. Computational study of the main flavonoids from Chrysobalanus icaco L. against NADPH-oxidase and in vitro antioxidant activity. Res. Soc Devel. 2022 11 6 e5011628542 e5011628542 10.33448/rsd-v11i6.28542
121 Wang W.W. Han R. He H.J. Li J. Chen S.Y. Gu Y. Xie C. Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson’s disease models. Aging (Albany NY) 2021 13 8 11738 11751 10.18632/aging.202868 33878030
122 Cui Z. Zhao X. Amevor F.K. Du X. Wang Y. Li D. Shu G. Tian Y. Zhao X. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Front. Immunol. 2022 13 943321 10.3389/fimmu.2022.943321 35935939
123 Xiao S. Lu Y. Wu Q. Yang J. Chen J. Zhong S. Eliezer D. Tan Q. Wu C. Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of β-strands. Int. J. Biol. Macromol. 2021 178 381 393 10.1016/j.ijbiomac.2021.02.210 33662414
124 Alikatte K. Palle S. Rajendra Kumar J. Pathakala N. Fisetin Improved Rotenone-induced behavioral deficits, oxidative changes, and mitochondrial dysfunctions in rat model of Parkinson’s disease. J. Diet. Suppl. 2021 18 1 57 71 10.1080/19390211.2019.1710646 31992104
125 Watanabe R. Kurose T. Morishige Y. Fujimori K. Protective effects of fisetin against 6-OHDA-induced apoptosis by activation of PI3K-Akt signaling in human neuroblastoma SH-SY5Y cells. Neurochem. Res. 2018 43 2 488 499 10.1007/s11064-017-2445-z 29204750
126 Maher P. Protective effects of fisetin and other berry flavonoids in Parkinson’s disease. Food Funct. 2017 8 9 3033 3042 10.1039/C7FO00809K 28714503
127 Rane A.R. Paithankar H. Hosur R.V. Choudhary S. Modulation of α-synuclein fibrillation by plant metabolites, daidzein, fisetin and scopoletin under physiological conditions. Int. J. Biol. Macromol. 2021 182 1278 1291 10.1016/j.ijbiomac.2021.05.071 33991558
128 Wang T.H. Wang S.Y. Wang X.D. Jiang H.Q. Yang Y.Q. Wang Y. Cheng J.L. Zhang C.T. Liang W.W. Feng H.L. Fisetin exerts antioxidant and neuroprotective effects in multiple mutant hSOD1 models of amyotrophic lateral sclerosis by activating ERK. Neuroscience 2018 379 152 166 10.1016/j.neuroscience.2018.03.008 29559385
129 Abou Baker D.H. Ibrahim B.M.M. Hassan N.S. Yousuf A.F. Gengaihi S.E. Exploiting Citrus aurantium seeds and their secondary metabolites in the management of Alzheimer disease. Toxicol. Rep. 2020 7 723 729 10.1016/j.toxrep.2020.06.001 32551234
130 Justin-Thenmozhi A. Dhivya Bharathi M. Kiruthika R. Manivasagam T. Borah A. Essa M.M. Attenuation of aluminum chloride-induced neuroinflammation and caspase activation through the AKT/GSK-3β pathway by hesperidin in wistar rats. Neurotox. Res. 2018 34 3 463 476 10.1007/s12640-018-9904-4 29687202
131 Mandour D.A. Bendary M.A. Alsemeh A.E. Histological and imunohistochemical alterations of hippocampus and prefrontal cortex in a rat model of Alzheimer like-disease with a preferential role of the flavonoid “hesperidin”. J. Mol. Histol. 2021 52 5 1043 1065 10.1007/s10735-021-09998-6 34170456
132 Elyasi L. Jahanshahi M. Jameie S.B. Hamid Abadi H.G. Nikmahzar E. Khalili M. Jameie M. Jameie M. 6-OHDA mediated neurotoxicity in SH-SY5Y cellular model of Parkinson disease suppressed by pretreatment with hesperidin through activating L-type calcium channels. J. Basic Clin. Physiol. Pharmacol. 2021 32 2 11 17 10.1515/jbcpp-2019-0270 32918805
133 Kesh S. Kannan R.R. Sivaji K. Balakrishnan A. Hesperidin downregulates kinases lrrk2 and gsk3β in a 6-OHDA induced Parkinson’s disease model. Neurosci. Lett. 2021 740 135426 10.1016/j.neulet.2020.135426 33075420
134 Poetini M.R. Araujo S.M. Trindade de Paula M. Bortolotto V.C. Meichtry L.B. Polet de Almeida F. Jesse C.R. Kunz S.N. Prigol M. Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in Drosophila melanogaster model of Parkinson’s disease. Chem. Biol. Interact. 2018 279 177 186 10.1016/j.cbi.2017.11.018 29191452
135 Subedi L. Gaire B.P. Neuroprotective effects of curcumin in cerebral ischemia: cellular and molecular mechanisms. ACS Chem. Neurosci. 2021 12 14 2562 2572 10.1021/acschemneuro.1c00153 34251185
136 Xu H. Nie B. Liu L. Zhang C. Zhang Z. Xu M. Mei Y. Curcumin prevents brain damage and cognitive dysfunction during ischemic-reperfusion through the regulation of miR-7-5p. Curr. Neurovasc. Res. 2020 16 5 441 454 10.2174/1567202616666191029113633 31660818
137 Çakmak G. Kaplan D.S. Yıldırım, C.; Ulusal, H.; Tarakçıoğlu, M.; Öztürk, Z.A. Improvement of cognitive deficit of curcumin on scopolamine-induced Alzheimer’s disease models. Caspian J. Intern. Med. 2022 13 1 16 22 35178203
138 Pluta R. Furmaga-Jabłońska, W.; Januszewski, S.; Czuczwar, S.J. Post-Ischemic brain neurodegeneration in the form of Alzheimer’s disease proteinopathy: Possible therapeutic role of curcumin. Nutrients 2022 14 2 248 10.3390/nu14020248 35057429
139 Reddy P.H. Manczak M. Yin X. Grady M.C. Mitchell A. Kandimalla R. Kuruva C.S. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. J. Investig. Med. 2016 64 8 1220 1234 10.1136/jim-2016-000240 27521081
140 ELBini-Dhouib, I.; Doghri, R.; Ellefi, A.; Degrach, I.; Srairi-Abid, N.; Gati, A. Curcumin attenuated neurotoxicity in sporadic animal model of Alzheimer’s disease. Molecules 2021 26 10 3011 10.3390/molecules26103011 34070220
141 Noor N.A. Hosny E.N. Khadrawy Y.A. Mourad I.M. Othman A.I. Aboul Ezz H.S. Mohammed H.S. Effect of curcumin nanoparticles on streptozotocin-induced male Wistar rat model of Alzheimer’s disease. Metab. Brain Dis. 2022 37 2 343 357 10.1007/s11011-021-00897-z 35048324
142 da Costa I.M. de Moura Freire M.A. de Paiva Cavalcanti J.R.L. de Araújo D.P. Norrara B. Moreira R.I.M.M. de Azevedo E.P. do Rego A.C.M. Filho I.A. Guzen F.P. Supplementation with Curcuma longa reverses neurotoxic and behavioral damage in models of Alzheimer’s disease: a systematic review. Curr. Neuropharmacol. 2019 17 5 406 421 10.2174/0929867325666180117112610 29338678
143 Mollazadeh H. Cicero A.F.G. Blesso C.N. Pirro M. Majeed M. Sahebkar A. Immune modulation by curcumin: The role of interleukin-10. Crit. Rev. Food Sci. Nutr. 2019 59 1 89 101 10.1080/10408398.2017.1358139 28799796
144 Nebrisi E.E. Neuroprotective activities of curcumin in Parkinson’s disease: A review of the literature. Int. J. Mol. Sci. 2021 22 20 11248 10.3390/ijms222011248 34681908
145 Abrahams S. Miller H.C. Lombard C. van der Westhuizen F.H. Bardien S. Curcumin pre-treatment may protect against mitochondrial damage in LRRK2-mutant Parkinson’s disease and healthy control fibroblasts. Biochem. Biophys. Rep. 2021 27 101035 10.1016/j.bbrep.2021.101035 34189277
146 Fikry H. Saleh L.A. Abdel Gawad S. Neuroprotective effects of curcumin on the cerebellum in a rotenone-induced Parkinson’s Disease Model. CNS Neurosci. Ther. 2022 28 5 732 748 10.1111/cns.13805 35068069
147 He H.J. Xiong X. Zhou S. Zhang X.R. Zhao X. Chen L. Xie C.L. Neuroprotective effects of curcumin via autophagy induction in 6-hydroxydopamine Parkinson’s models. Neurochem. Int. 2022 155 105297 10.1016/j.neuint.2022.105297 35122926
148 Ramires Júnior O.V. Alves B.S. Barros P.A.B. Rodrigues J.L. Ferreira S.P. Monteiro L.K.S. Araújo G.M.S. Fernandes S.S. Vaz G.R. Dora C.L. Hort M.A. Nanoemulsion improves the neuroprotective effects of curcumin in an experimental model of Parkinson’s disease. Neurotox. Res. 2021 39 3 787 799 10.1007/s12640-021-00362-w 33860897
149 Chetty D. Abrahams S. Coller R. Carr J. Kenyon C. Bardien S. Movement of prion-like α‐synuclein along the gut–brain axis in Parkinson’s disease: A potential target of curcumin treatment. Eur. J. Neurosci. 2021 54 2 4695 4711 10.1111/ejn.15324 34043864
150 Elifani F. Amico E. Pepe G. Capocci L. Castaldo S. Rosa P. Montano E. Pollice A. Madonna M. Filosa S. Calogero A. Maglione V. Crispi S. Di Pardo A. Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington’s disease. Hum. Mol. Genet. 2019 28 23 ddz247 10.1093/hmg/ddz247 31630202
151 Aditi K. Singh A. Shakarad M.N. Agrawal N. Management of altered metabolic activity in Drosophila model of Huntington’s disease by curcumin. Exp. Biol. Med. (Maywood) 2022 247 2 152 164 10.1177/15353702211046927 34743577
152 Chico L. Ienco E.C. Bisordi C. Lo Gerfo A. Petrozzi L. Petrucci A. Mancuso M. Siciliano G. Amyotrophic lateral sclerosis and oxidative stress: A double-blind therapeutic trial after curcumin supplementation. CNS Neurol. Disord. Drug Targets 2018 17 10 767 779 10.2174/1871527317666180720162029 30033879
153 Patel K. Patel D.K. The Beneficial Role of Rutin, A naturally occurring flavonoid in health promotion and disease prevention: A systematic review and update. Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases. 2nd ed Academic Press 2019 457 479
154 Sun X. Li L. Dong Q.X. Zhu J. Huang Y. Hou S. Yu X. Liu R. Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease. J. Neuroinflammation 2021 18 1 131 10.1186/s12974-021-02182-3 34116706
155 Ouyang Q. Liu K. Zhu Q. Deng H. Le Y. Ouyang W. Yan X. Zhou W. Tong J. Brain-penetration and neuron-targeting DNA nanoflowers co-delivering miR-124 and rutin for synergistic THerapy of Alzheimer’s disease. Small 2022 18 14 2107534 10.1002/smll.202107534 35182016
156 Cordeiro L.M. Soares M.V. da Silva A.F. Machado M.L. Bicca O.B.F. da Silveira T.L. Arantes L.P. Soares F.A.A. Neuroprotective effects of rutin on ASH neurons in Caenorhabditis elegans model of Huntington’s disease. Nutr. Neurosci. 2021 1 14 10.1080/1028415X.2021.1956254 34311678
157 Cordeiro L.M. Machado M.L. da Silva A.F. Obetine B.F.B. da Silveira T.L. Soares F.A.A. Arantes L.P. Rutin protects Huntington’s disease through the insulin/IGF1 (IIS) signaling pathway and autophagy activity: Study in Caenorhabditis elegans model. Food Chem. Toxicol. 2020 141 111323 10.1016/j.fct.2020.111323 32278002
158 Suganya S.N. Sumathi T. Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington’s disease model in rats. Metab. Brain Dis. 2017 32 2 471 481 10.1007/s11011-016-9929-4 27928694
159 Abdelfattah M.S. Badr S.E.A. Lotfy S.A. Attia G.H. Aref A.M. Abdel Moneim A.E. Kassab R.B. Rutin and selenium co-administration reverse 3-nitropropionic acid-induced neurochemical and molecular impairments in a mouse model of Huntington’s disease. Neurotox. Res. 2020 37 1 77 92 10.1007/s12640-019-00086-y 31332714
160 Neta F. Da Costa I. Lima F. Fernandes L. Cavalcanti J. Freire M. Lucena E.D.S. Do Rêgo A.M. De Azevedo E. Guzen F. Effects of Mucuna pruriens (L.) supplementation on experimental models of Parkinson’s disease: A systematic review. Pharmacogn. Rev. 2018 12 23 78 84
161 Nayak V.S. Kumar N. D’Souza A.S. Nayak S.S. Cheruku S.P. Pai K.S.R. The effects of Mucuna pruriens extract on histopathological and biochemical features in the rat model of ischemia. Neuroreport 2017 28 18 1195 1201 10.1097/WNR.0000000000000888 28953092
162 Duttaroy A.K. Health effects of terpenoids.Evidence-Based Nutrition and Clinical Evidence of Bioactive Foods in Human Health and Disease. Duttaroy A.K. Academic Press 2021 413 424 10.1016/B978-0-12-822405-2.00017-7
163 Song Y. Wang Y. Zheng Y. Liu T. Zhang C. Crocins: A comprehensive review of structural characteristics, pharmacokinetics and therapeutic effects. Fitoterapia 2021 153 104969 10.1016/j.fitote.2021.104969 34147548
164 Taheri R. Hadipour E. Tayarani-Najaran Z. Crocin protects against beta-amyloid peptide-induced apoptosis in PC12 cells via the PI3 K pathway. Curr. Mol. Pharmacol. 2021 14 4 627 634 10.2174/1874467213666201012160401 33045973
165 Yousefsani B.S. Mehri S. Pourahmad J. Hosseinzadeh H. Protective effect of crocin against mitochondrial damage and memory deficit induced by beta-amyloid in the hippocampus of rats. Iran. J. Pharm. Res. 2021 20 2 79 94 34567148
166 Hadipour M. Bahari Z. Afarinesh M.R. Jangravi Z. Shirvani H. Meftahi G.H. Administering crocin ameliorates anxiety-like behaviours and reduces the inflammatory response in amyloid-beta induced neurotoxicity in rat. Clin. Exp. Pharmacol. Physiol. 2021 48 6 877 889 10.1111/1440-1681.13494 33686675
167 Saeedi M. Rashidy-Pour A. Association between chronic stress and Alzheimer’s disease: Therapeutic effects of Saffron. Biomed. Pharmacother. 2021 133 110995 10.1016/j.biopha.2020.110995 33232931
168 Mohammadzadeh L. Hosseinzadeh H. Abnous K. Razavi B.M. Neuroprotective potential of crocin against malathion-induced motor deficit and neurochemical alterations in rats. Environ. Sci. Pollut. Res. Int. 2018 25 5 4904 4914 10.1007/s11356-017-0842-0 29204935
169 Chongtham A. Yoo J.H. Chin T.M. Akingbesote N.D. Huda A. Khoshnan A. Gut bacteria regulate the pathogenesis of Huntington’s disease in Drosophila. bioRxiv 2021 16 10.1101/2021.08.12.456124
170 Siahaan E.A. Pangestuti R. Pratama I.S. Putra Y. Kim S-K. Beneficial effects of astaxanthin in cosmeceuticals with focus on emerging market trends. Global Perspectives on Astaxanthin. Ravishankar G.A. Ranga R.A. Academic Press 2021 557 568
171 Alghazwi M. Smid S. Musgrave I. Zhang W. In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ1-42) toxicity and aggregation. Neurochem. Int. 2019 124 215 224 10.1016/j.neuint.2019.01.010 30639263
172 Rahman S.O. Panda B.P. Parvez S. Kaundal M. Hussain S. Akhtar M. Najmi A.K. Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Aβ peptides in animal model of Alzheimer’s disease. Biomed. Pharmacother. 2019 110 47 58 10.1016/j.biopha.2018.11.043 30463045
173 Sakayanathan P. Loganathan C. Kandasamy S. Ramanna R.V. Poomani K. Thayumanavan P. In vitro and in silico analysis of novel astaxanthin-s-allyl cysteine as an inhibitor of butyrylcholinesterase and various globular forms of acetylcholinesterases. Int. J. Biol. Macromol. 2019 140 1147 1157 10.1016/j.ijbiomac.2019.08.168 31442505
174 Chen C-C. Lee H-C. Chang J-H. Chen S-S. Li T-C. Tsai C-H. Cho D-Y. Hsieh C-L. Chinese herb Astragalus membranaceus enhances recovery of hemorrhagic stroke: double-blind, placebo-controlled, randomized study. Evid-Based Compl Alter Med 2012 2012 708452
175 Costa I.M. Lima F.O.V. Fernandes L.C.B. Norrara B. Neta F.I. Alves R.D. Cavalcanti J.R.L.P. Lucena E.E.S. Cavalcante J.S. Rego A.C.M. Filho I.A. Queiroz D.B. Freire M.A.M. Guzen F.P. Astragaloside IV supplementation promotes a neuroprotective effect in experimental models of neurological disorders: a systematic review. Curr. Neuropharmacol. 2019 17 7 648 665 10.2174/1570159X16666180911123341 30207235
176 Shen D.F. Qi H.P. Ma C. Chang M.X. Zhang W.N. Song R.R. Astaxanthin suppresses endoplasmic reticulum stress and protects against neuron damage in Parkinson’s disease by regulating miR-7/SNCA axis. Neurosci. Res. 2021 165 51 60 10.1016/j.neures.2020.04.003 32333925
177 Akinade T.C. Babatunde O.O. Adedara A.O. Adeyemi O.E. Otenaike T.A. Ashaolu O.P. Johnson T.O. Terriente-Felix A. Whitworth A.J. Abolaji A.O. Protective capacity of carotenoid trans-astaxanthin in rotenone-induced toxicity in Drosophila melanogaster. Sci. Rep. 2022 12 1 4594 10.1038/s41598-022-08409-4 35301354
178 Yang J. Li J. Lu J. Zhang Y. Zhu Z. Wan H. Synergistic protective effect of astragaloside IV–tetramethylpyrazine against cerebral ischemic-reperfusion injury induced by transient focal ischemia. J. Ethnopharmacol. 2012 140 1 64 72 10.1016/j.jep.2011.12.023 22207211
179 Sánchez-Illana Á. Piñeiro-Ramos J.D. Ramos-Garcia V. Ten-Doménech I. Vento M. Kuligowski J. Chapter Three - Oxidative stress biomarkers in the preterm infant. Adv. Clin. Chem. Makowski G.S. Elsevier 2021 Vol. 102 127 189
180 Singhrang N. Tocharus C. Thummayot S. Sutheerawattananonda M. Tocharus J. Protective effects of silk lutein extract from Bombyx mori cocoons on β-Amyloid peptide-induced apoptosis in PC12 cells. Biomed. Pharmacother. 2018 103 582 587 10.1016/j.biopha.2018.04.045 29677545
181 Ademowo O.S. Dias I.H.K. Diaz-Sanchez L. Sanchez-Aranguren L. Stahl W. Griffiths H.R. Partial mitigation of oxidized phospholipid-mediated mitochondrial dysfunction in neuronal cells by oxocarotenoids. J. Alzheimers Dis. 2020 74 1 113 126 10.3233/JAD-190923 31985464
182 Fernandes E.J. Poetini M.R. Barrientos M.S. Bortolotto V.C. Araujo S.M. Santos Musachio E.A. De Carvalho A.S. Leimann F.V. Gonçalves O.H. Ramborger B.P. Roehrs R. Prigol M. Guerra G.P. Exposure to lutein-loaded nanoparticles attenuates Parkinson’s model-induced damage in Drosophila melanogaster: restoration of dopaminergic and cholinergic system and oxidative stress indicators. Chem. Biol. Interact. 2021 340 109431 10.1016/j.cbi.2021.109431 33716020
183 Binawade Y. Jagtap A. Neuroprotective effect of lutein against 3-nitropropionic acid-induced Huntington’s disease-like symptoms: possible behavioral, biochemical, and cellular alterations. J. Med. Food 2013 16 10 934 943 10.1089/jmf.2012.2698 24138168
184 Wani A. Al Rihani S.B. Sharma A. Weadick B. Govindarajan R. Khan S.U. Sharma P.R. Dogra A. Nandi U. Reddy C.N. Bharate S.S. Singh G. Bharate S.B. Vishwakarma R.A. Kaddoumi A. Kumar A. Crocetin promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated AMPK pathway. Autophagy 2021 17 11 3813 3832 10.1080/15548627.2021.1872187 33404280
185 Zhang J. Wang Y. Dong X. Liu J. Crocetin attenuates inflammation and amyloid-β; accumulation in APPsw transgenic mice. Immun. Ageing 2018 15 1 24 10.1186/s12979-018-0132-9 30450117
186 Dong N. Dong Z. Chen Y. Gu X. Crocetin alleviates inflammation in MPTP-induced Parkinson’s disease models through improving mitochondrial functions. Parkinsons Dis. 2020 2020 1 9 10.1155/2020/9864370 33101635
187 Montgomery Hays B. Hudson T. 166 - Endometriosis. Textbook of Natural Medicine 5th ed; Pizzorno, J.E.; Murray, M.T., Eds.; Churchill Livingstone: St. Louis, MO, 2020 1287 1295 e1283 10.1016/B978-0-323-43044-9.00166-7
188 Hira S. Saleem, U.; Anwar, F.; Sohail, M.F.; Raza, Z.; Ahmad, B. β-Carotene: A natural compound improves cognitive impairment and oxidative stress in a mouse model of streptozotocin-induced Alzheimer’s disease. Biomolecules 2019 9 9 441 10.3390/biom9090441 31480727
189 Kim J.H. Hwang J. Shim E. Chung E.J. Jang S.H. Koh S.B. Association of serum carotenoid, retinol, and tocopherol concentrations with the progression of Parkinson’s Disease. Nutr. Res. Pract. 2017 11 2 114 120 10.4162/nrp.2017.11.2.114 28386384
190 Przybylska S. Lycopene – a bioactive carotenoid offering multiple health benefits: a review. Int. J. Food Sci. Technol. 2020 55 1 11 32 10.1111/ijfs.14260
191 Huang C. Wen C. Yang M. Gan D. Fan C. Li A. Li Q. Zhao J. Zhu L. Lu D. Lycopene protects against t-BHP-induced neuronal oxidative damage and apoptosis via activation of the PI3K/Akt pathway. Mol. Biol. Rep. 2019 46 3 3387 3397 10.1007/s11033-019-04801-y 31006097
192 Putteeraj M. Lim W.L. Teoh S.L. Yahaya M.F. Flavonoids and its neuroprotective effects on brain ischemia and neurodegenerative diseases. Curr. Drug Targets 2018 19 14 1710 1720 10.2174/1389450119666180326125252 29577854
193 Tripathi R. Shalini R. Singh R.K. 7 - Prophyletic origin of algae as potential repository of anticancer compounds. Evolutionary Diversity as a Source for Anticancer Molecules; Srivastava, A.K.; Kannaujiya, V.K.; Singh, R.K. Singh D. Academic Press 2021 155 189 10.1016/B978-0-12-821710-8.00007-2
194 Nazih H. Bard J-M. Microalgae in human health: Interest as a functional food. Microalgae in Health and Disease Prevention; Levine, I.A. Fleurence J. Academic Press 2018 211 226 10.1016/B978-0-12-811405-6.00010-4
195 Xiang S. Liu F. Lin J. Chen H. Huang C. Chen L. Zhou Y. Ye L. Zhang K. Jin J. Zhen J. Wang C. He S. Wang Q. Cui W. Zhang J. Fucoxanthin inhibits β-amyloid assembly and attenuates β-amyloid oligomer-induced cognitive impairments. J. Agric. Food Chem. 2017 65 20 4092 4102 10.1021/acs.jafc.7b00805 28478680
196 Lee A.H. Shin H.Y. Park J.H. Koo S.Y. Kim S.M. Yang S.H. Fucoxanthin from microalgae Phaeodactylum tricornutum inhibits pro-inflammatory cytokines by regulating both NFκB and NLRP3 inflammasome activation. Sci. Rep. 2021 11 1 543 10.1038/s41598-020-80748-6 33436909
197 Wu W. Han H. Liu J. Tang M. Wu X. Cao X. Zhao T. Lu Y. Niu T. Chen J. Fucoxanthin prevents 6-OHDA-induced neurotoxicity by targeting Keap1. Oxid. Med. Cell. Long., 2021 2021
198 Choudhary S. Singh P.K. Verma H. Singh H. Silakari O. Success stories of natural product-based hybrid molecules for multi-factorial diseases. Eur. J. Med. Chem. 2018 151 62 97 10.1016/j.ejmech.2018.03.057 29605809
199 Singh A. Mahajan S.D. Kutscher H.L. Kim S. Prasad P.N. Curcumin-pluronic nanoparticles: A theranostic nanoformulation for Alzheimer’s disease. Crit. Rev. Biomed. Eng. 2020 48 3 153 168 10.1615/CritRevBiomedEng.2020034302 33389893
200 Mursaleen L. Somavarapu S. Zariwala M.G. Deferoxamine and curcumin loaded nanocarriers protect against rotenone-induced neurotoxicity. J. Parkinsons Dis. 2020 10 1 99 111 10.3233/JPD-191754 31868679
201 Pan Q. Ban Y. Xu L. Silibinin-albumin nanoparticles: Characterization and biological evaluation against oxidative stress-stimulated neurotoxicity associated with Alzheimer’s disease. J. Biomed. Nanotechnol. 2021 17 6 1123 1130 10.1166/jbn.2021.3038 34167626
202 Mandal S. Debnath K. Jana N.R. Jana N.R. Trehalose-conjugated, catechin-loaded polylactide nanoparticles for improved neuroprotection against intracellular polyglutamine aggregates. Biomacromolecules 2020 21 4 1578 1586 10.1021/acs.biomac.0c00143 32105465
203 Debnath K. Jana N.R. Jana N.R. Quercetin encapsulated polymer nanoparticle for inhibiting intracellular polyglutamine aggregation. ACS Appl. Bio Mater. 2019 2 12 5298 5305 10.1021/acsabm.9b00518 35021530
204 Cano A. Ettcheto M. Espina M. Auladell C. Folch J. Kühne B.A. Barenys M. Sánchez-López E. Souto E.B. García M.L. Turowski P. Camins A. Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. Nanomedicine (Lond.) 2021 16 1 19 35 10.2217/nnm-2020-0239 33410329
205 Lima B.S. Campos C.A. da Silva Santos A.C.R. Santos V.C.N. Trindade G.G.G. Shanmugam S. Pereira E.W.M. Marreto R.N. Duarte M.C. Almeida J.R.G.S. Quintans J.S.S. Quintans L.J. Jr Araújo A.A.S. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects. Food Chem. Toxicol. 2019 126 15 24 10.1016/j.fct.2019.01.038 30738132
206 Manta K. Papakyriakopoulou P. Chountoulesi M. Diamantis D.A. Spaneas D. Vakali V. Naziris N. Chatziathanasiadou M.V. Andreadelis I. Moschovou K. Athanasiadou I. Dallas P. Rekkas D.M. Demetzos C. Colombo G. Banella S. Javornik U. Plavec J. Mavromoustakos T. Tzakos A.G. Valsami G. Preparation and biophysical characterization of quercetin inclusion complexes with β-cyclodextrin derivatives to be formulated as possible nose-to-brain quercetin delivery systems. Mol. Pharm. 2020 17 11 4241 4255 10.1021/acs.molpharmaceut.0c00672 32986435
207 Wong K.H. Xie Y. Huang X. Kadota K. Yao X.S. Yu Y. Chen X. Lu A. Yang Z. Delivering crocetin across the blood brain barrier by using γ-cyclodextrin to treat Alzheimer’s disease. Sci. Rep. 2020 10 1 3654 10.1038/s41598-020-60293-y 32107408
208 Zhang L. Yang S. Wong L.R. Xie H. Ho P.C.L. In vitro and in vivo comparison of curcumin-encapsulated chitosan-coated Poly(lactic-co-glycolic acid) nanoparticles and curcumin/hydroxypropyl-β-cyclodextrin inclusion complexes administered intranasally as therapeutic strategies for Alzheimer’s disease. Mol. Pharm. 2020 17 11 4256 4269 10.1021/acs.molpharmaceut.0c00675 33084343
209 Kumar R. Kumar R. Khurana N. Singh S.K. Khurana S. Verma S. Sharma N. Kapoor B. Vyas M. Khursheed R. Awasthi A. Kaur J. Corrie L. Enhanced oral bioavailability and neuroprotective effect of fisetin through its SNEDDS against rotenone-induced Parkinson’s disease rat model. Food Chem. Toxicol. 2020 144 111590 10.1016/j.fct.2020.111590 32710995
210 Kumar R. Kumar R. Khurana N. Singh S.K. Khurana S. Verma S. Sharma N. Vyas M. Dua K. Khursheed R. Awasthi A. Vishwas S. Improved neuroprotective activity of Fisetin through SNEDDS in ameliorating the behavioral alterations produced in rotenone-induced Parkinson’s model. Environ. Sci. Pollut. Res. Int. 2022 29 33 50488 50499 10.1007/s11356-022-19428-z 35230633
211 Sangsen Y. Sooksawate T. Likhitwitayawuid K. Sritularak B. Wiwattanapatapee R. A self-microemulsifying formulation of oxyresveratrol prevents amyloid beta protein-induced neurodegeneration in mice. Planta Med. 2018 84 11 820 828 10.1055/s-0043-125337 29301146
212 Huo X. Zhang Y. Jin X. Li Y. Zhang L. A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer’s disease. J. Photochem. Photobiol. B 2019 190 98 102 10.1016/j.jphotobiol.2018.11.008 30504054
213 Mazibuko Z. Indermun S. Govender M. Kumar P. Du Toit L.C. Choonara Y.E. Modi G. Naidoo D. Pillay V. Targeted delivery of amantadine-loaded methacrylate nanosphere-ligands for the potential treatment of amyotrophic lateral sclerosis. J. Pharm. Pharm. Sci. 2018 21 1 94 109 10.18433/jpps29595 29510799
214 Agwa M.M. Abdelmonsif D.A. Khattab S.N. Sabra S. Self- assembled lactoferrin-conjugated linoleic acid micelles as an orally active targeted nanoplatform for Alzheimer’s disease. Int. J. Biol. Macromol. 2020 162 246 261 10.1016/j.ijbiomac.2020.06.058 32531361
215 Chibhabha F. Yang Y. Ying K. Jia F. Zhang Q. Ullah S. Liang Z. Xie M. Li F. Non-invasive optical imaging of retinal Aβ plaques using curcumin loaded polymeric micelles in APP swe/PS1 ΔE9 transgenic mice for the diagnosis of Alzheimer’s disease. J. Mater. Chem. B Mater. Biol. Med. 2020 8 33 7438 7452 10.1039/D0TB01101K 32662804
216 Singh M. Thakur V. Deshmukh R. Sharma A. Rathore M.S. Kumar A. Mishra N. Development and characterization of morin hydrate-loaded micellar nanocarriers for the effective management of Alzheimer’s disease. J. Microencapsul. 2018 35 2 137 148 10.1080/02652048.2018.1441916 29448848
217 Mursaleen L. Noble B. Somavarapu S. Zariwala M.G. Micellar nanocarriers of hydroxytyrosol are protective against Parkinson’s related oxidative stress in an in vitro hCMEC/D3-SH-SY5Y co-culture system. Antioxidants 2021 10 6 887 10.3390/antiox10060887 34073115
218 D’Ambrosio D. Panina-Bordignon P. Sinigaglia F. Chemokine receptors in inflammation: an overview. J. Immunol. Methods 2003 273 1-2 3 13 10.1016/S0022-1759(02)00414-3 12535793
219 Grivennikov S.I. Greten F.R. Karin M. Immunity, inflammation, and cancer. Cell 2010 140 6 883 899 10.1016/j.cell.2010.01.025 20303878
220 Nathan C. Ding A. Nonresolving inflammation. Cell 2010 140 6 871 882 10.1016/j.cell.2010.02.029 20303877
221 Flower R.J. The development of COX2 inhibitors. Nat. Rev. Drug Discov. 2003 2 3 179 191 10.1038/nrd1034 12612644
222 Takeuchi O. Akira S. Pattern recognition receptors and inflammation. Cell 2010 140 6 805 820 10.1016/j.cell.2010.01.022 20303872
223 Medzhitov R. Inflammation 2010: New adventures of an old flame. Cell 2010 140 6 771 776 10.1016/j.cell.2010.03.006 20303867
224 Chertov O. Yang D. Howard O.M.Z. Oppenheim J.J. Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunol. Rev. 2000 177 1 68 78 10.1034/j.1600-065X.2000.17702.x 11138786
225 Stichtenoth D.O. Frölich J.C. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003 63 1 33 45 10.2165/00003495-200363010-00003 12487621
226 Feghali C.A. Wright T.M. Cytokines in acute and chronic inflammation. Front. Biosci. 1997 2 1 d12 d26 9159205
227 Arango Duque G. Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol. 2014 5 491 10.3389/fimmu.2014.00491 25339958
228 Zhou Y. Hong Y. Huang H. Triptolide attenuates inflammatory response in membranous glomerulo-nephritis rat via downregulation of NF-κB signaling pathway. Kidney Blood Press. Res. 2016 41 6 901 910 10.1159/000452591 27871079
229 Fritz J.H. Girardin S.E. How Toll-like receptors and Nod-like receptors contribute to innate immunity in mammals. J. Endotoxin Res. 2005 11 6 390 394 10.1177/09680519050110060301 16303096
230 Hanna V.S. Hafez E.A.A. Synopsis of arachidonic acid metabolism: A review. J. Adv. Res. 2018 11 23 32 10.1016/j.jare.2018.03.005 30034873
231 Dennis E.A. Norris P.C. Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol. 2015 15 8 511 523 10.1038/nri3859 26139350
232 Gaddi A. Cicero A.F.G. Pedro E.J. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch. Gerontol. Geriatr. 2004 38 3 201 212 10.1016/j.archger.2003.10.001 15066307
233 Rådmark O. Werz O. Steinhilber D. Samuelsson B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2015 1851 4 331 339 10.1016/j.bbalip.2014.08.012 25152163
234 Poetker D.M. Reh D.D. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol. Clin. North Am. 2010 43 4 753 768 10.1016/j.otc.2010.04.003 20599080
235 Day R.O. Graham G.G. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ 2013 346 f3195 23757736
236 Harirforoosh S. Asghar W. Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J. Pharm. Pharm. Sci. 2014 16 5 821 847 10.18433/J3VW2F 24393558
237 Rao P.P.N. Kabir S.N. Mohamed T. Nonsteroidal anti-inflammatory drugs (NSAIDs): progress in small molecule drug development. Pharmaceuticals (Basel) 2010 3 5 1530 1549 10.3390/ph3051530 27713316
238 Mukherjee D. Nissen S.E. Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 286 8 954 959 10.1001/jama.286.8.954 11509060
239 Arora M. Choudhary S. Singh P.K. Sapra B. Silakari O. Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review. Life Sci. 2020 251 117631 10.1016/j.lfs.2020.117631 32251635
240 Meyer-Kirchrath J. Schrör K. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Curr. Med. Chem. 2000 7 11 1121 1129 10.2174/0929867003374219 11032962
241 Jose M-G. Lina B. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr. Pharm. Des. 2007 13 22 2215 2227 10.2174/138161207781368774 17691994
242 Rao P. Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci. 2008 11 2 81 10.18433/J3T886 19203472
243 Newman D.J. Cragg G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 2020 83 3 770 803 10.1021/acs.jnatprod.9b01285 32162523
244 Addington O.C. Newman R.A. Method of treating neurological conditions with oleandrin. US Patent US 9,877,979, 2018
245 Mazed M.A. Mazed S. Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance. US Patent US 8017147 B2, 2011
246 Gennari G. Panfilo S. Pharmaceutical compositions containing phosphatidylserine and curcumin. US Patent US 9381204 B2, 2016
247 Tan J. Luo D. Shytle R.D. Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism. US Patent US 8778894 B2, 2014
248 Crowley K.L. Buccal and sublingual cannabinoid formulations and method of making the same. EP Patent EP 3160451 B1 2021
249 Rupasinghe H.P. Robertson G.S. Phenolic compositions derived from apple skin and uses thereof. US Patent US 9511107 B2 2016
250 Soman G.S. Phadke S.G. Herbal composition for reducing ADD/ ADHD and method thereof. US Patent US 8394429 B2, 2013
251 Baraona R.M. Sepúlveda L.Q. Saavedra I.S. Salas R.S. Salas V.S. Nutraceutical composition that comprises extract of andean shilajit, for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral aging. US Patent US 8784804 B2, 2014
252 Guy G. Platt B. Cannabinoid-containing plant extracts as neuroprotective agents. US Patent US 8673368 B2 2014
253 Choi P. Castillo G. Nguyen B. Snow A. Cummings J. Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders. CA Patent CA 2440293 C, 2012
254 Atanasov A.G. Zotchev S.B. Dirsch V.M. Supuran C.T. Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 2021 20 3 200 216 10.1038/s41573-020-00114-z 33510482
255 Chemat F. Abert-Vian M. Fabiano-Tixier A.S. Strube J. Uhlenbrock L. Gunjevic V. Cravotto G. Green extraction of natural products. Origins, current status, and future challenges. Trends Analyt. Chem. 2019 118 248 263 10.1016/j.trac.2019.05.037
256 Shinde P. Banerjee P. Mandhare A. Marine natural products as source of new drugs: a patent review (2015–2018). Expert Opin. Ther. Pat. 2019 29 4 283 309 10.1080/13543776.2019.1598972 30902039
257 McGonigle I.V. Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rights. J. Law Biosci. 2016 3 1 217 226 10.1093/jlb/lsw003 27774245
258 Heffernan O. Why a landmark treaty to stop ocean biopiracy could stymie research. Nature 2020 580 7801 20 22 10.1038/d41586-020-00912-w 32221504
259 Rahman M.H. Bajgai J. Fadriquela A. Sharma S. Trinh T.T. Akter R. Jeong Y.J. Goh S.H. Kim C.S. Lee K.J. Therapeutic potential of natural products in treating neurodegenerative disorders and their future prospects and challenges. Molecules 2021 26 17 5327 10.3390/molecules26175327 34500759
260 Di Paolo M. Papi L. Gori F. Turillazzi E. Natural products in neurodegenerative diseases: A great promise but an ethical challenge. Int. J. Mol. Sci. 2019 20 20 5170 10.3390/ijms20205170 31635296
